

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 July 2006 (06.07.2006)

PCT

(10) International Publication Number  
WO 2006/071740 A2

(51) International Patent Classification: Not classified

Crest Place, San Diego, CA 92129 (US). BJENNIN, Christina [SI/US]; 239 26th Street, Del Mar, CA 92014 (US).

(21) International Application Number:  
PCT/US2005/046654

(74) Agents: SPRUCE, Lyle et al.; ARENA PHARMACEUTICALS, INC., 6166 Nancy Ridge Drive, San Diego, California 92121-3223 (US).

(22) International Filing Date:  
21 December 2005 (21.12.2005)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GI, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:  
60/638,667 23 December 2004 (23.12.2004) US  
60/688,901 8 June 2005 (08.06.2005) US

(71) Applicant (for all designated States except US): ARENA PHARMACEUTICALS, INC. [US/US]; 6166 Nancy Ridge Drive, San Diego, 592121-3223 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,


(72) Inventors; and

{Continued on next page}

(75) Inventors/Applicants (for US only): BEHAN, Dominic P. [US/US]; 11479 Weatherhill Way, San Diego, CA 92131 (US). SMITH, Brian M. [US/US]; 13182 Mesa

(54) Title: 5HT<sub>2C</sub> RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE

## A. Compound 1



(57) Abstract: The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I); or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity.

WO 2006/071740 A2



FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

**5HT<sub>2C</sub> RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE****Field of the Invention**

The present invention relates to compounds which act as modulators of 5HT<sub>2C</sub> receptors, 5 compositions including the compounds, and methods of using the compounds and compositions.

**Background of the Invention**

Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer 10 and gallbladder disease.

Obesity is now a major healthcare issue in the Western World and increasingly in some third world countries. The increase in numbers of obese people is due largely to the increasing preference for high fat content foods but also the decrease in activity in most people's lives. In the last 10 years there has been a 30% increase in the incidence of obesity in the USA such that 15 currently about 30% of the population of the USA is now considered obese.

Whether someone is classified as overweight or obese is generally determined on the basis of their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m<sup>2</sup>). Thus, the units of BMI are kg/m<sup>2</sup> and it is possible to calculate the BMI range associated with minimum mortality in each decade of life. Overweight is defined as a BMI in the 20 range 25-30 kg/m<sup>2</sup>, and obesity as a BMI greater than 30 kg/m<sup>2</sup> (see Table 1 below).

**TABLE 1: CLASSIFICATION OF WEIGHT BY  
BODY MASS INDEX (BMI)**

BMI	CLASSIFICATION
< 18.5	Underweight
18.5-24.9	Normal
25.0-29.9	Overweight
30.0-34.9	Obesity (Class I)
35.0-39.9	Obesity (Class II)
>40	Extreme Obesity (Class III)

25 As the BMI increases there is an increased risk of death from a variety of causes that are independent of other risk factors. The most common diseases associated with obesity are cardiovascular disease (particularly hypertension), diabetes (obesity aggravates the development of diabetes), gall bladder disease (particularly cancer) and diseases of reproduction. Research has shown that even a modest reduction in body weight can correspond to a significant reduction in the

risk of developing coronary heart disease.

There are problems however with the BMI definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose tissue). To account for this, obesity can also be defined on the basis of body fat content: greater than 25% in males and greater than 30% in females.

Obesity considerably increases the risk of developing cardiovascular diseases as well. Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular complications induced by obesity. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and the risk of cardiac insufficiency and of cerebral vascular accidents would decrease by 35%. The incidence of coronary diseases is doubled in subjects less than 50 years of age who are 30% overweight. The diabetes patient faces a 30% reduced lifespan. After age 45, people with diabetes are about three times more likely than people without diabetes to have significant heart disease and up to five times more likely to have a stroke. These findings emphasize the inter-relations between risk factors for diabetes and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of obesity (Perry, I. J., et al., *BMJ* 310, 560-564 (1995)).

Diabetes has also been implicated in the development of kidney disease, eye diseases and nervous system problems. Kidney disease, also called nephropathy, occurs when the kidney's "filter mechanism" is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma. Finally, diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death.

The first line of treatment is to offer diet and life style advice to patients such as reducing the fat content of their diet and increasing their physical activity. However, many patients find this difficult and need additional help from drug therapy to maintain results from these efforts.

Most currently marketed products have been unsuccessful as treatments for obesity because of a lack of efficacy or unacceptable side-effect profiles. The most successful drug so far was the indirectly acting 5-hydroxytryptamine (5-HT) agonist d-fenfluramine (Redux<sup>TM</sup>) but reports of cardiac valve defects in up to one third of patients led to its withdrawal by the FDA in 1998.

In addition, two drugs have recently been launched in the USA and Europe: Orlistat (Xenical<sup>TM</sup>), a drug that prevents absorption of fat by the inhibition of pancreatic lipase, and Sibutramine (Reductil<sup>TM</sup>), a 5-HT/noradrenaline re-uptake inhibitor. However, side effects associated with these products may limit their long-term utility. Treatment with Xenical<sup>TM</sup> is

reported to induce gastrointestinal distress in some patients, while Sibutramine has been associated with raised blood pressure in some patients.

Serotonin (5-HT) neurotransmission plays an important role in numerous physiological processes both in physical and in psychiatric disorders. 5-HT has been implicated in the regulation 5 of feeding behavior. 5-HT appears to work by inducing a feeling of fullness or satiety so eating stops earlier and fewer calories are consumed. It has been shown that a stimulatory action of 5-HT on the 5HT<sub>2C</sub> receptor plays an important role in the control of eating and in the anti-obesity effect of d-fenfluramine. As the 5-HT<sub>2C</sub> receptor is expressed in high density in the brain (notably in the limbic structures, extrapyramidal pathways, thalamus and hypothalamus i.e. PVN and DMH, and 10 predominantly in the choroid plexus) and is expressed in low density or is absent in peripheral tissues, a selective 5-HT<sub>2C</sub> receptor agonist can be a more effective and safe anti-obesity agent. Also, 5-HT<sub>2C</sub> knockout mice are overweight with cognitive impairment and susceptibility to 15 seizure.


It is believed that 5HT<sub>2C</sub> may play a role in obsessive compulsive disorder, some forms of depression, and epilepsy. Accordingly, agonists can have anti-panic properties, and properties 15 useful for the treatment of sexual dysfunction.

In sum, the 5HT<sub>2C</sub> receptor is a receptor target for the treatment of obesity and psychiatric disorders, and it can be seen that there is a need for selective 5HT<sub>2C</sub> agonists which safely decrease food intake and body weight. The present invention is directed to these, as well as other, important 20 ends.

### Summary of the Invention

In a *first* aspect, the invention features a composition comprising phentermine and a selective 5HT-2C receptor agonist.

25 In a *second* aspect, the invention features a composition according to the first aspect where the selective 5HT-2C receptor agonist has Formula (I):



or a pharmaceutically acceptable salt, solvate or hydrate thereof  
wherein:

30 R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;  
R<sub>2</sub> is C<sub>1-8</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-8</sub> alkyl, -C(=O)-O-C<sub>1-8</sub> alkyl, -C(=O)-NH-C<sub>1-8</sub> alkyl,  
OH, or CH<sub>2</sub>OH;

$R_{21}$  is  $H_1$

or  $R_2$  and  $R_{2a}$  together form  $-CH_2-CH_2-$ ;

R<sub>3</sub> and R<sub>4</sub> are each independently H, halogen, perhaloalkyl, CN, OR<sub>5</sub>, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, OH, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

or  $R_3$  and  $R_4$  together with the atoms to which they are attached can form a 5- or 6-member heterocyclic ring having one O atom;

10 each  $R_5$  is independently  $C_{1-8}$  alkyl,  $C_{1-8}$  alkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or perhaloalkyl, or allyl; and

R<sub>6</sub> is H or C<sub>1-8</sub> alkyl.

In a *third* aspect, the invention features a composition according to the second aspect wherein:

15 R<sub>3</sub> is halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>2</sub>)<sub>2</sub>, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alky, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl; and

$R_1$  is H, halogen, perhaloalkyl, CN,  $SR_5$ ,  $NHR_5$ ,  $N(R_5)_2$ , aryl, or heteroaryl.

20 wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

wherein heteroaryl is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, furanyl, pyranyl, thienyl, benzimidazolyl, quinolinyl, isoquinolinyl, oxazolyl, thiazolyl or thiadiazolyl.

In a *fourth* aspect, the invention features a composition according to the second or third aspect wherein R<sub>1</sub> is H. In addition, the fourth aspect features a composition according to the second or third aspect wherein R<sub>1</sub> is methyl.

30 In a *fifth* aspect, the invention features a composition according to the second, third, or fourth aspect wherein R<sub>2</sub> is methyl, ethyl, n-propyl or isopropyl. In addition, the fifth aspect features a composition according to the second, third, or fourth aspect wherein R<sub>2</sub> is methyl or ethyl. Further, the fifth aspect features a composition according to the second, third, or fourth aspect wherein R<sub>2</sub> and R<sub>2a</sub> together form  $-\text{CH}_2\text{CH}_2-$ .

In a *sixth* aspect, the invention features a composition according to the second through fifth aspect wherein  $R_3$  is chlorine. In addition, the sixth aspect features a composition according to the second through fifth aspect wherein  $R_3$  is bromine. Further, the sixth aspect features a

composition according to the second through fifth aspect wherein R<sub>3</sub> is perhaloalkyl. Also, the sixth aspect features a composition according to the second through fifth aspect wherein R<sub>3</sub> is CF<sub>3</sub>. Further, the sixth aspect features a composition according to the second through fifth aspect wherein R<sub>3</sub> is selected from the group consisting of thiienyl, furanyl, pyrrolyl, pyrazolyl and imidazolyl.

5 In a *seventh* aspect, the invention features a composition according to the second through sixth aspect wherein R<sub>4</sub> is selected from the group consisting of thiienyl, furanyl, pyrrolyl, pyrazolyl and imidazolyl optionally substituted with one or two substituents selected from halogen or methyl. In addition, the seventh aspect features a composition according to the second through sixth aspect 10 wherein R<sub>4</sub> is phenyl optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy.

In an *eighth* aspect, the invention features a composition according to the second aspect wherein:

15 R<sub>2</sub> is methyl, ethyl, isopropyl, or CH<sub>2</sub>OH; or R<sub>2</sub> and R<sub>2a</sub> taken together form -CH<sub>2</sub>CH<sub>2</sub>-;

R<sub>3</sub> is halogen, or a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S, and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl; R<sub>4</sub> is H, a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, or phenyl 20 optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy;

R<sub>6</sub> is H or methyl, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

In addition, the eighth aspect features a composition of the second aspect wherein:

25 R<sub>1</sub> is H;

R<sub>2</sub> is methyl;

R<sub>3</sub> is chlorine, bromine, or thiienyl;

R<sub>4</sub> is pyrazolyl-3-yl or phenyl wherein said pyrazolyl-3-yl optionally has up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, and said phenyl optionally has a single 30 halogen substituent; and

R<sub>6</sub> is H; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

Further, the eighth aspect features a composition of the second aspect wherein:

35 R<sub>1</sub> is H or Me;

R<sub>2</sub> is Me, Et, or OH;

R<sub>2a</sub> is H;

R<sub>3</sub> is F, Cl, Br, I, CF<sub>3</sub>, or 2-chlorophenyl;

R<sub>4</sub> is H; and

R<sub>6</sub> is H.

In addition, the eighth aspect features a composition of the second aspect wherein:

R<sub>1</sub> is H;

5 R<sub>2</sub> is C<sub>1-8</sub> alkyl;

R<sub>2a</sub> is H;

R<sub>3</sub> is halogen;

R<sub>4</sub> is H; and

R<sub>6</sub> is H.

10 In a *ninth* aspect, the invention features a composition according to the first or second aspect wherein said selective 5HT-2C receptor agonist is selected from the group consisting of:

8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

15 8-trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-trifluoromethyl-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-chloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-bromo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-iodo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

20 7,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7,8-dichloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

8-chloro-7-fluoro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

25 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

In addition, the ninth aspect features a composition according to the first or second aspect wherein said selective 5HT-2C receptor agonist is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof.

In a *tenth* aspect, the invention features a composition according to the first through ninth aspect further comprising a pharmaceutically acceptable carrier.

In an *eleventh* aspect, the invention features a method of decreasing food intake of a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal. In one embodiment, the amount of (R)-8-chloro-1-methyl-2,3,4,5-

tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in decreasing food intake in said mammal.

5 In a *twelfth* aspect, the invention features a method of inducing satiety in a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in inducing satiety in said mammal. In one embodiment, the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in 10 inducing satiety in said mammal.

15 In a *thirteenth* aspect, the invention features a method of controlling weight gain of a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in controlling weight gain in said mammal. In one embodiment, the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in controlling weight gain in said mammal.

20 In a *fourteenth* aspect, the invention features a method of prophylaxis or treatment of obesity comprising administering to a patient in need of such prophylaxis or treatment a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal. In one embodiment, the 25 amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in decreasing food intake in said mammal.

30 In some embodiments, some of the foregoing methods of the invention further comprising the step of identifying a subject, said subject being in need of decreasing food intake, controlling weight gain, or treating obesity, wherein said identifying step is performed prior to administering to said subject said pharmaceutically effective amount of said compound or composition of the invention.

Applicants reserve the right to exclude any one or more of the compounds from any of the embodiments of the invention. Applicant additionally reserves the right to exclude any disorder from any of the embodiments of the invention.

### Brief Description of the Figures

Figures 1A-1G illustrate the effects of seven different 5HT-2C receptor agonist compounds described in the invention on food intake in food-deprived rats.

5 Figure 2 shows the supra additive (synergistic) effect of phentermine and the selective 5HT-2C receptor agonist 8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Cmpd A) on feeding in rats.

10 Figures 3A and 3B show the supra additive (synergistic) effect of phentermine and the selective 5HT-2C receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Cmpd B) on food intake in female (Figure 3A) and male (Figure 3B) rats.

15 Figures 4A and 4B show the supra additive (synergistic) effect of phentermine and the selective 5HT-2C receptor agonist (R)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine (Cmpd C) on food intake in female (Figure 4A) and male (Figure 4B) rats.

### Detailed Description of the Invention

The present invention relates to the combination of 5HT-2C receptor agonist compounds with other agents in order to decrease certain 5HT-2C receptor related behaviors such as feeding. While the 5HT-2C receptor agonist compounds described in the invention can be employed as the sole active agent in a pharmaceutical (i.e., mono-therapy), they can advantageously be used in combination with other active ingredients (i.e., combination-therapy) which can facilitate the therapeutic effect of the compound. Therefore, one aspect of the present invention includes methods of prophylaxis and/or treatment of a 5HT-2C receptor related condition such as obesity, or a condition related thereto, comprising administering to an individual in need of said prophylaxis and/or treatment a combination comprising an amount of a selective 5HT-2C receptor agonist in combination with an amount of one or more additional pharmaceutical agent as described herein. In one embodiment, the amount of the selective 5HT-2C receptor agonist and the amount of the one or more additional pharmaceutical agents alone are therapeutically sub-effective in the prophylaxis and/or treatment of the condition but when combined these compounds act synergistically to prevent or treat the condition.

30 Suitable pharmaceutical agents that can be used in combination with the selective 5HT-2C receptor agonists include, for example, anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, serotonin and norepinephrine reuptake inhibitors (for example, sibutramine), sympathomimetic agents,  $\beta_3$  adrenergic receptor agonists, dopamine agonists (for example, bromocriptine), melanocyte-stimulating hormone receptor analogs, 35 cannabinoid 1 receptor antagonists (for example, SR141716: *N*-(piperidin-1-yl)-5-(4-

chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide], melanin concentrating hormone antagonists, leptins (the OB protein), leptin analogues, leptin receptor agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e., Orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Y antagonists, thyromimetic agents, 5 dehydroepiandrosterone or an analogue thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, urocortin binding protein antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (such as Axokine™ available from Regeneron Pharmaceuticals, Inc., Tarrytown, NY and Procter & Gamble Company, Cincinnati, OH), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3 receptor antagonists or 10 reverse agonists, neuromedin U receptor agonists, noradrenergic anorectic agents (for example, phentermine, mazindol and the like) and appetite suppressants (for example, bupropion).

Other anti-obesity agents, including the agents set forth in *infra*, are well known, or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.

In some embodiments, the anti-obesity agents are selected from the group consisting of 15 phentermine, orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine. In one embodiment, the anti-obesity agent is phentermine. In a further embodiment, compositions of the present invention and combination therapies are administered in conjunction with exercise and/or a sensible diet.

It will be understood that the scope of combination therapy of the compounds of the 20 present invention with other anti-obesity agents, anorectic agents, appetite suppressant and related agents is not limited to those listed above, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment of overweight and obese individuals.

Other suitable pharmaceutical agents, in addition to anti-obesity agents, that can be used in 25 combination with the compounds of the present invention include agents useful in the treatment of concomitant diseases. For example, individuals who are overweight or obese increase their risk of morbidity and mortality arising from concomitant diseases, such as, but not limited to, congestive heart failure, type II diabetes, atherosclerosis, dyslipidemia, hyperinsulinemia, hypertension, insulin resistance, hyperglycemia, retinopathy, nephropathy and neuropathy. Treatment for one or 30 more of the diseases cited herein include the use of one or more pharmaceutical agents known in the art belonging to the classes of drugs referred to, but not limited to, the following: sulfonylureas, meglitinides, biguanides,  $\alpha$ -glucosidase inhibitors, peroxisome proliferators-activated receptor- $\gamma$  (i.e., PPAR- $\gamma$ ) agonists, insulin, insulin analogues, HMG-CoA reductase inhibitors, cholesterol-lowering drugs (for example, fibrates that include: fenofibrate, bezafibrate, gemfibrozil, clofibrate, 35 and the like; bile acid sequestrants which include: cholestyramine, colestipol and the like; statins, and niacin), antiplatelet agents (for example, aspirin and adenosine diphosphate receptor

antagonists that include: clopidogrel, ticlopidine and the like), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and adiponectin.

It will be understood that the scope of combination therapy of the compounds of the present invention with other pharmaceutical agents is not limited to those listed herein, *supra* or 5 *infra*, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment diseases, conditions or disorders that are linked to overweight and obese individuals.

Combination therapies have been used in the treatment of diseases; however, care must be taken when combining drugs since certain drugs can interact in a harmful manner. The 10 combination of two agents that treat the same condition is generally expected to result in an additive effect meaning that the degree of the effect is the sum of the effect of each drug alone. Applicants disclose herein that the combination of a selective 5HT-2C agonist and another drug such as phentermine can result in a supra additive or synergistic effect on food intake (see Figure 2, 3A and B, 4A and B). A synergistic effect means that the decrease in food intake observed with 15 the combination therapy is greater than that seen by adding the decrease in food intake of each compound together. One advantage of using a synergistic combination therapy is that less of each compound is required to achieve a significant decrease in food intake and so fewer side effects can result from treatment. In some cases, side effects are not seen at the lower doses used. Also, in some cases, the side effect profile of one drug can mitigate or average out the side effect profile of 20 the other drug. For example, one of the drugs may result in increased blood pressure and the other drug results in lowered blood pressure so that the combination therapy does not effect blood pressure. Another potential advantage of combination therapy is that, since less compound is required, the cost of therapy can be reduced.

This application incorporates by reference, in their entirety, U.S. Provisional Application 25 Number 60/372,058, filed April 12, 2002; U.S. Provisional Patent Application Number 60/405,495, filed August 23, 2002; U.S. Provisional Patent Application Number 60/434,607, filed December 18, 2002; U.S. Non-Provisional Patent Application No. 10/410,991, filed April 10, 2003 and U.S. Non-Provisional Patent Application No. 10/917,979, filed August 13, 2004. This application claims priority to, and incorporates by reference in their entirety, U.S. Provisional 30 Application Number 60/638,667, filed December 23, 2004, and U.S. Provisional Application Number 60/688,901, filed June 8, 2005.

In one aspect, the invention provides a composition comprising phentermine and a selective 5HT-2C receptor agonist.

Phentermine (1,1-Dimethyl-2-phenyl-ethylamine) includes phentermine derivatives or 35 pharmaceutically acceptable salts thereof, such as, but not limited to, chlorphentermine (2-(4-

(Chloro-phenyl)-1,1-dimethyl-ethylamine) and the like. In one embodiment, phentermine is in the HCl salt form.

As used herein, the term "agonist" is intended to mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes. In 5 the context of the present invention, a pharmaceutical composition comprising a 5HT<sub>2C</sub> receptor agonist of the invention can be utilized for modulating the activity of the 5HT<sub>2C</sub> receptor, decreasing food intake, inducing satiation (i.e., the feeling of fullness), controlling weight gain, treating obesity, decreasing body weight and/or affecting metabolism such that the recipient loses weight and/or maintains weight. Such pharmaceutical compositions can be used in the context of 10 disorders and/or diseases where weight gain is a component of the disease and/or disorder such as, for example, obesity.


The term "antagonist" is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the 15 intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.

As used herein the term "selective 5HT-2C receptor agonist" means an agonist compound that is selective for 5HT-2C receptor compared to other receptors that decrease food intake. For example, a selective 5HT-2C receptor agonist has a significantly higher binding affinity for the 20 5HT-2C receptor than for another receptor that can decrease food intake such as the 5HT-1b receptor. Therefore, for example, a selective 5HT-2C receptor agonist can have 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, or 150-fold or more higher binding affinity for the 5HT-2C receptor than for another receptor such as the 5HT-1b receptor. As understood by one skilled in the art, selectivity can be determined, for example, using a 25 receptor binding assay or a functional assay. One way to assess selectivity is to perform a feeding assay as disclosed herein (see Example 2) with a potential selective 5HT-2C receptor agonist and then challenge the animals with a selective 5HT-2C antagonist, for example, SB 242084 (Sigma). If the food intake effect is abolished (or very significantly decreased) then the effect is deemed to be occurring through the 5HT-2C receptor and not through a different receptor.

The term "selective 5HT-2C receptor agonist" does not include compounds such as 30 dextfenfluramine which are 5HT-releasing agents or compounds such as fluoxetine which are 5HT uptake inhibitors. In addition, the term "selective 5HT-2C receptor agonist" does not include non-selective 5HT agonists such as *m*-chlorophenylpiperazine (*m*CPP) or *m*-trifluoromethylphenylpiperazine (TFMPP) which have significant effects at the 5HT-1b receptor. 35 For example, TFMPP causes decreased food intake; however, the decrease in food intake is not abolished when a selective 5HT-2C antagonist such as SB 242084 is added.

As disclosed herein, compositions of the invention can comprise phentermine and a selective 5HT-2C receptor agonist. The phentermine and selective 5HT-2C receptor agonist can be delivered as separate entities or the phentermine and selective 5HT-2C receptor agonist can be combined to form one entity. For example, phentermine and selective 5HT-2C receptor agonist can be delivered as two separate pills or capsules or they can be combined to form one pill or capsule.

5 The invention also provides a composition comprising phentermine and a selective 5HT-2C receptor agonist where the selective 5HT-2C receptor agonist has Formula (I):



10 or a pharmaceutically acceptable salt, solvate or hydrate thereof  
wherein:

R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>1-8</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-8</sub> alkyl, -C(=O)-O-C<sub>1-8</sub> alkyl, -C(=O)-NH-C<sub>1-8</sub> alkyl, OH, or CH<sub>2</sub>OH;

15 R<sub>2a</sub> is H;

or R<sub>2</sub> and R<sub>2a</sub> together form -CH<sub>2</sub>-CH<sub>2</sub>-;

R<sub>3</sub> and R<sub>4</sub> are each independently H, halogen, perhaloalkyl, CN, OR<sub>5</sub>, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, OH, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;


20 or R<sub>3</sub> and R<sub>4</sub> together with the atoms to which they are attached can form a 5- or 6-member heterocyclic ring having one O atom;

each R<sub>5</sub> is independently C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkenyl, aryl, heteroaryl, arylalkyl,

25 heteroarylalkyl or perhaloalkyl, or allyl; and

R<sub>6</sub> is H or C<sub>1-8</sub> alkyl.

Some embodiments of the present invention pertain to a composition comprising phentermine and a selective 5HT-2C receptor agonist where the selective 5HT-2C receptor agonist has Formula (I):



or a pharmaceutically acceptable salt, solvate or hydrate thereof  
wherein:

5           R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>1-8</sub> alkyl, -CH<sub>2</sub>-O-C<sub>1-8</sub> alkyl, -C(=O)-O-C<sub>1-8</sub> alkyl, -C(=O)-NH-C<sub>1-8</sub> alkyl, OH, or CH<sub>2</sub>OH;

R<sub>2a</sub> is H;

or R<sub>2</sub> and R<sub>2a</sub> together form -CH<sub>2</sub>-CH<sub>2</sub>-;

R<sub>3</sub> is halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, aryl, or heteroaryl,

10           wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

R<sub>4</sub> is H, halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, aryl, or

15           heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

20           each R<sub>5</sub> is independently C<sub>1-8</sub> alkyl, C<sub>1-8</sub> alkenyl, aryl, heteroaryl, arylalkyl, heteroaryalkyl or perhaloalkyl, or allyl; and

R<sub>6</sub> is H or C<sub>1-8</sub> alkyl;

25           wherein heteroaryl is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, furanyl, pyranyl, thieryl, benzimidazolyl, quinolinyl, isoquinolinyl, oxazolyl, thiazolyl or thiadiazolyl;

              or a pharmaceutically acceptable salt, solvate or hydrate thereof  
provided that:


(i) if R<sub>6</sub> is other than H, then neither R<sub>3</sub> nor R<sub>4</sub> can be H;

(ii) if R<sub>1</sub> and R<sub>2</sub> are methyl, and R<sub>4</sub> is H, then R<sub>3</sub> cannot be NHR<sub>5</sub> or

N(R<sub>5</sub>)<sub>2</sub>; and

30           (iii) if R<sub>1</sub> and R<sub>2</sub> are methyl, and R<sub>4</sub> is H, then R<sub>3</sub> cannot be imidazole, substituted imidazole, or an imidazole derivative.

Some embodiments of the present invention pertain to a composition comprising phenetermine and a selective 5HT-2C receptor agonist where the selective 5HT-2C receptor agonist has Formula (I):



5

wherein:

R1 is: -H or C<sub>1-8</sub>alkyl;

R2 is: C<sub>1-8</sub>alkyl, -CH<sub>2</sub>-O-C<sub>1-8</sub>alkyl, -C(=O)-O-C<sub>1-8</sub>alkyl, -C(=O)-NH- C<sub>1-8</sub>alkyl, -OH, or -CH<sub>2</sub>OH;

10 R2a is: -H;

or R<sub>2</sub> and R<sub>2a</sub> together form -CH<sub>2</sub>-CH<sub>2</sub>;

R<sub>3</sub> is: halogen; perhaloalkyl; or a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S;

R<sub>4</sub> is -H, halogen, perhaloalkyl, -CN, -OR<sub>5</sub>, -SR<sub>5</sub>, -NHR<sub>5</sub>, -N(R<sub>5</sub>)<sub>2</sub>, -OH, aryl, or heteroaryl, 15 wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub>alkyl, halogen, perhaloalkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub>alkyl;

or:

20 R<sub>3</sub> and R<sub>4</sub> together with the atoms to which they are attached form a 5- or 6-member heterocyclic ring having one O atom;

each R<sub>5</sub> is independently C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or perhaloalkyl, or allyl; and

R<sub>6</sub> is -H or C<sub>1-8</sub>alkyl;

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

25 provided that:

if R<sub>6</sub> is other than -H, then R<sub>4</sub> cannot be -H; and

if R<sub>1</sub> and R<sub>2</sub> are methyl, and R<sub>4</sub> is -H, then R<sub>3</sub> cannot be imidazole, substituted imidazole, or an imidazole derivative;

and wherein:

30 aryl denotes a monocyclic or polycyclic aromatic group having from 3 to 14 carbon atoms; heteroaryl denotes a monocyclic or polycyclic aromatic group having from 3 to 14 carbon atoms, and from 1 to 4 ring heteroatoms selected from O, N, and S;

alkoxy denotes -O-alkyl;

$C_{1-8}alkyl$  denotes a straight chain, branched, or cyclic hydrocarbon group having from 1 to 8 carbon atoms;

$C_{1-8}alkenyl$  denotes a straight chain, branched, or cyclic hydrocarbon group having from 1 to 8 carbon atoms and at least one double bond;

5       alkyl, other than  $C_{1-8}alkyl$ , denotes methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl, n-pentyl, isopentyl, tert-pentyl, cyclopentyl, cyclopentylmethyl, n-hexyl, or cyclohexyl.

It is appreciated that compounds of Formula (I) can have one or more chiral centers, and  
10      exist as enantiomers or diastereomers. The invention is to be understood to extend to all such  
enantiomers, diastereomers and mixtures thereof, including racemates. Formula (I) and the  
formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless  
stated or shown otherwise.

It is also appreciated that certain features of the invention, which are, for clarity, described  
15      in the context of separate embodiments, may also be provided in combination in a single  
embodiment. Conversely, various features of the invention, which are, for brevity, described in the  
context of a single embodiment, may also be provided separately or in any suitable  
subcombination. All combinations of the embodiments pertaining to the chemical groups  
represented by the variables (e.g.  $R_1, R_2, R_{2a}, R_3, R_4, R_5, R_6$ , etc.) contained within the generic  
20      chemical formulae described herein [e.g. Formula (I) etc.] are specifically embraced by the present  
invention just as if they were explicitly disclosed, to the extent that such combinations embrace  
compounds that result in stable compounds (i.e., compounds that can be isolated, characterized and  
tested for biological activity). In addition, all subcombinations of the chemical groups listed in the  
embodiments describing such variables, as well as all subcombinations of uses and medical  
25      indications described herein, are also specifically embraced by the present invention just as if each  
of such subcombination of chemical groups and subcombination of uses and medical indications  
were explicitly disclosed herein.

As used herein, "substituted" indicates that at least one hydrogen atom of the chemical  
30      group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group  
can be monovalent or divalent. When the substituent or group is divalent, then it is understood  
that this group is further substituted with another substituent or group. When a chemical group  
herein is "substituted" it may have up to the full valance of substitution; for example, a methyl  
group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2  
substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5 substituents, a naphthyl group can  
35      be substituted by 1, 2, 3, 4, 5, 6, or 7 substituents and the like. Likewise, "substituted with one or  
more substituents" refers to the substitution of a group with one substituent up to the total number

of substituents physically allowed by the group. Further, when a group is substituted with more than one group they can be identical or they can be different.

As used herein, the term "alkyl" is intended to denote hydrocarbon groups including straight chain, branched and cyclic hydrocarbons, including for example but not limited to methyl, 5 ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl, n-pentyl, isopentyl, tert-pentyl, cyclopentyl, cyclopentylmethyl, n-hexyl, cyclohexyl, and the like. Throughout this specification, it should be understood that the term alkyl is intended to encompass both non-cyclic hydrocarbon groups and cyclic hydrocarbon groups. In some embodiments of the compounds of the invention, alkyl groups are non-cyclic. In further 10 embodiments, alkyl groups are cyclic, and in further embodiments, alkyl groups are both cyclic and noncyclic. Where no preference is specified, the term "alkyl" is intended to denote groups that are both cyclic and non-cyclic.

As used herein, the term "alkenyl" is intended to denote hydrocarbon compounds including straight chain, branched and cyclic hydrocarbons that contain at least one double bond, 15 including for example but not limited to allyl, 2-methyl-allyl, 4-but-3-enyl, 4-hex-5-enyl, 3-methyl-but-2-enyl, cyclohex-2-enyl and the like.

As used herein, the term "halogen" has its normal meaning of period seven elements, including F, Cl, Br and I.

The term "alkoxy" is intended to denote substituents of the formula 20 -O-alkyl, including -O-allyl. The term "lower" when used in connection with substituents such as alkyl indicates 6 carbons or less.

The term "arylalkyl" or "aralkyl" is intended to denote an alkyl group that bears an aryl substituent, for example a benzyl group. The term "alkylaryl" or "alkaryl" is intended to denote an aryl group that bears an alkyl substituent, for example a 4-methylphenyl group.

25 As used herein, the term "aryl" is intended to mean monocyclic and polycyclic aromatic groups. Although aryl groups can include as few as 3 carbon atoms, preferred aryl groups have 6 to about 14 carbon atoms, more preferably 6 to about 10 carbon atoms. Examples of aryl groups include but are not limited to phenyl, naphthyl, anthracyl, phenanthryl and pyrenyl.

The term "heteroaryl" is intended to denote an aryl group that contains at least one, and 30 preferably from one to four ring "hetero" (i.e., non-carbon, e.g., O, N or S) atom. Examples of "heteroaryl" groups are radicals derived from 5- and 6-member aryl ring compounds having from one to four nitrogen, sulfur and/or oxygen atoms, for example pyrrole, pyrazole, imidazole, triazole, tetrazole, pyridine, pyrimidine, furan, pyran, thiophene, benzimidazole, quinoline, isoquinoline, oxazole, thiazole, and thiadiazole.

35 As used herein the term heteroarylalkyl means an alkyl group that bears a heteroaryl substituent, for example a group having the structure -CH<sub>2</sub>-pyrrole- 2-yl.

The term "substituted thiazole" means a radical derived from thiazole that bears at least one substituent group. The term "thiazole derivative" means a fused ring system in which one of the fused rings is thiazole.

5 The term "substituted imidazole" means a radical derived from imidazole that bears at least one substituent group. The term "imidazole derivative" means a fused ring system in which one of the fused rings is imidazole.

Certain substituents of the compounds disclosed herein can optionally be substituted, i.e., they can optionally bear further substituent groups. Some preferred substituent groups include halogen, lower alkyl (including but not limited to methyl, ethyl, isopropyl, cyclopropyl, tert-butyl, 10 and methylcyclopropyl), alkoxy, mono-, di- or trihaloalkoxy (e.g., -O-CX<sub>3</sub> where X is halogen), -(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>NHBoc, -N(R<sub>4a</sub>)(R<sub>4b</sub>), phenyl, methoxyphenyl and naphthyl.

15 At various places in the present specification substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C<sub>1-8</sub> alkyl" is specifically intended to individually disclose methyl, ethyl, C<sub>3</sub> alkyl, C<sub>4</sub> alkyl, C<sub>5</sub> alkyl, C<sub>6</sub> alkyl, C<sub>7</sub> alkyl and C<sub>8</sub> alkyl.

20 Additionally, compounds of the present invention encompass all pharmaceutically acceptable salts, solvates, and particularly hydrates, thereof; including but not limited to, phentermine, phentermine derivatives (e.g., chlorphentermine), selective 5HT-2C receptor agonists (e.g., compounds of Formula (I)), and the like.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I): wherein:

25 R<sub>3</sub> is halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>3</sub>)<sub>2</sub>, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl; and

30 R<sub>4</sub> is H, halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>3</sub>)<sub>2</sub>, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

wherein heteroaryl is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, furanyl, pyranyl, thiienyl, benzimidazolyl, quinolinyl, isoquinolinyl, oxazolyl, thiazolyl or thiadiazolyl.

35 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>1</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>1</sub> is methyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>2</sub> is methyl, ethyl, n-propyl or isopropyl.

5 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>2</sub> is methyl or ethyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>2</sub> and R<sub>2a</sub> together form -CH<sub>2</sub>CH<sub>2</sub>.

10 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>3</sub> is chlorine.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>3</sub> is bromine.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>3</sub> is perhaloalkyl. In some embodiments, R<sub>3</sub> is CF<sub>3</sub>.

15 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>3</sub> is selected from the group consisting of thiienyl, furanyl, pyrrolyl, pyrazolyl and imidazolyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein R<sub>4</sub> is selected from the group consisting of thiienyl, furanyl, pyrrolyl, pyrazolyl 20 and imidazolyl optionally substituted with one or two substituents selected from halogen or methyl or wherein R<sub>4</sub> is phenyl optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2</sub> is methyl, ethyl, isopropyl, or CH<sub>2</sub>OH; or R<sub>2</sub> and R<sub>2a</sub> taken together form 25 -CH<sub>2</sub>CH<sub>2</sub>.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>3</sub> is halogen, or a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S, and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl.

30 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>4</sub> is H, a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, or phenyl optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>6</sub> is H or methyl.

35 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>1</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2</sub> is methyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>3</sub> is chlorine, bromine, or thiienyl.

5 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>4</sub> is pyrazolyl-3-yl or phenyl wherein said pyrazolyl-3-yl optionally has up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, and said phenyl optionally has a single halogen substituent.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of 10 Formula (I) wherein: R<sub>6</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>1</sub> is H or Me.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2</sub> is Me, Et, or OH.

15 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2a</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>3</sub> is F, Cl, Br, I, CF<sub>3</sub>, or 2-chlorophenyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of 20 Formula (I) wherein: R<sub>4</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>6</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>1</sub> is H.

25 In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2</sub> is C<sub>1-8</sub> alkyl.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>2a</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of 30 Formula (I) wherein: R<sub>3</sub> is halogen.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>4</sub> is H.

In some embodiments of the present invention, the selective 5HT-2C receptor agonist is of Formula (I) wherein: R<sub>6</sub> is H.

35 The invention provides a composition comprising phentermine and a selective 5HT-2C receptor agonist as described herein wherein said selective 5HT-2C receptor agonist is selected

from the group consisting of:

8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
5 8-trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-trifluoromethyl-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-bromo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-iodo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
10 7,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
7,8-dichloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and  
8-chloro-7-fluoro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
15 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

The compounds of the invention may contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. The compounds can be, for example, racemates or optically active forms. The optically active forms can be obtained by resolution of the racemates or by asymmetric synthesis. In some embodiments, compounds of  
20 Formula (I) are *R* enantiomers. In some embodiments, compounds of Formula (I) are *S* enantiomers. In some embodiments, compounds of Formula (I) are varying mixtures of enantiomers.

In one embodiment, the invention provides a composition comprising phentermine and a selective 5HT-2C receptor agonist wherein said selective 5HT-2C receptor agonist is (R)-8-chloro-25 1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof.

The compounds and compositions according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.  
30 Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfiric, tartaric, oxalic, p-toluenesulfonic and the like, such as the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) and incorporated herein by reference.  
35

The acid addition salts can be obtained as the direct products of compound synthesis. In

the alternative, the free base can be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.

5 Compositions of the invention may conveniently be administered in unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art, for example, as described in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, PA, 1980).

The invention also provides compositions of the invention, as described above, further comprising a pharmaceutically acceptable carrier. For example, the invention provides a 10 composition comprising phentermine and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier. Thus, the invention provides pharmaceutical compositions containing phentermine and a selective 5HT-2C agonist. A pharmaceutical composition is a 15 composition comprising at least one active ingredient and at least one ingredient that is not an active ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to use for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).

According to a further aspect of the invention, the compositions of the invention are provided for use in therapy. The compositions can be used in the prophylaxis or treatment of 20 disorders associated with 5-HT<sub>2C</sub> receptor function.

According to a further aspect of the invention, there is provided use of a composition of the invention in the manufacture of a medicament for the prophylaxis or treatment of the disorders disclosed herein. In a preferred embodiment, there is provided a use of a composition of the invention in the manufacture of a medicament for the prophylaxis or treatment of obesity.

25 The data developed herein supports the conclusion that the presently disclosed compositions of the invention are of use for the treatment or prophylaxis of clinical obesity or overweight disorders in mammals, including, but not limited to, human. Compositions of the present invention can be administered by oral, sublingual, parenteral, rectal, topical administration or by a transdermal patch. Transdermal patches dispense a drug at a controlled rate by presenting 30 the drug for absorption in an efficient manner with a minimum of degradation of the drug. Typically, transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner. One of ordinary skill in the art will understand and appreciate the techniques appropriate for manufacturing a desired efficacious transdermal patch based upon the needs of the artisan.

35 In addition to the neutral forms of compositions of the present invention, by appropriate addition of an ionizable substituent, which does not alter the receptor specificity of the compound,

physiologically acceptable salts of the compositions may also be formed and used as therapeutic agents. Different amounts of the compositions of the present invention will be required to achieve the desired biological effect. The amount will depend on factors such as the specific composition, the use for which it is intended, the means of administration, and the condition of the treated individual - all of these dosing parameters are within the level of one of ordinary skill in the medicinal arts. A typical dose can be expected to fall in the range of 0.001 to 200 mg per kilogram of body weight of the mammal. For example a typical dose can fall in the range of 0.001 to 0.01, 0.01 to 0.1, 0.1 to 1, 1 to 10, 10 to 100, or 100 to 200 mg per kilogram of body weight of the mammal. Unit doses may contain from 1 to 200 mg of the compositions of the present invention and can be administered one or more times a day, individually or in multiples. For example, unit doses can contain from 1 to 10, 10 to 50, 50 to 100, 100 to 150 or 150 to 200 mg of the compositions of the invention and can be administered one or more times a day, individually or in multiples.

The compositions of the present invention can be combined with the carrier in either solid or liquid form in a unit dose formulation. The pharmaceutical carrier must be compatible with the other ingredients in the composition and must be tolerated by the individual recipient. Other physiologically active ingredients can be incorporated into the pharmaceutical composition of the invention if desired, and if such ingredients are compatible with the other ingredients in the composition. Formulations can be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if necessary, forming the resulting mixture into a desired shape.


Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting lubricants, and disintegrants can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations can be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants can be added to the liquid preparations. Parenteral dosage forms can be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.

It is noted that the compositions of the invention are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of compositions of the invention for the treatment of obesity in domestic animals (e.g., cats and dogs), and in other domestic animals where

no disease or disorder is evident (e.g., food-oriented animals such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compositions in such settings.

5 The selective 5HT-2C receptor agonists of Formula (I) in the compositions can be readily prepared according to a variety of synthetic manipulations, all of which would be familiar to one skilled in the art. A representative general synthesis is set forth below in Scheme I

**Scheme I**  
**GENERAL REACTION SCHEME**



Those of skill in the art will appreciate that a wide variety of selective 5HT-2C receptor agonist compounds described in the invention can be prepared according to

Scheme I. For example, by starting with an appropriately substituted 2-phenyl ethylamino compound A' having any of a wide variety of substituents R<sub>1</sub> and R<sub>2</sub>, the corresponding 7- and/or 8-substituted 1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (compound H) can be prepared. N-alkylation can be accomplished by, for example, treatment with excess 5 paraformaldehyde (for methylation) or a higher order aldehyde, followed by reduction with NaBH<sub>3</sub>CN according to the general procedure of synthetic examples 9 and 10, *infra*. In addition, by starting with an appropriately substituted 1-alkyl-2-phenyl ethylamino compound A' having any of a wide variety of substituents R<sub>1</sub> and R<sub>2</sub>, the corresponding 7- and/or 8-substituted 2,5-dialkyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine compound can be prepared.

10 In the synthesis of many compounds of the invention, protecting groups can be required to protect various functionality or functionalities during the synthesis. Representative protecting groups suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, *Protective Groups in Organic Synthesis*, 2d ed, John Wiley & Sons, New York, 1991, the disclosure of which is incorporated herein by reference in its entirety.

15 The invention provides a method of decreasing food intake of a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising a selective 5HT-2C receptor agonist and an amount of phentermine, wherein said selective 5HT-2C receptor agonist and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal. For example, the invention provides a method of decreasing food intake of a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-20 benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal. In one embodiment, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the amount of phentermine alone are 25 therapeutically effective(i.e. showing a statistically significant effect) in decreasing food intake in said mammal and the compounds are provided in amounts to give a synergistic effect in decreasing food intake in said mammal.

30 In one embodiment, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the

amount of phentermine alone are therapeutically sub-effective in decreasing food intake in said mammal. As used herein, "therapeutically sub-effective" means that the 5HT-2C agonist and/or phentermine are provided in amounts that do not have a statistically significant effect on the measured parameter. For example, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the amount of phentermine alone can be therapeutically ineffective in decreasing food intake in said mammal. Since the combination of a selective 5HT-2C receptor agonist and phentermine have a synergistic effect (see, for example, Figure 2, Figures 3A and B, and Figures 4A and B), the combination therapy can be therapeutically effective while each of the compounds separately are therapeutically sub-effective (which includes, for example, when the compound or compounds are ineffective). In a method of treatment, a therapeutically effective dose of the combination of the selective 5HT-2C receptor agonist and phentermine is used.

The invention also provides a method of inducing satiety in a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of a selective 5HT-2C receptor agonist and an amount of phentermine, wherein said selective 5HT-2C receptor agonist and phentermine are provided in amounts to give a synergistic effect in inducing satiety in said mammal. For example, the invention provides a method of inducing satiety in a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and/or an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in inducing satiety in said mammal. In one embodiment, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the amount of phentermine alone are therapeutically sub-effective or ineffective in inducing satiety in said mammal.

In addition, the invention provides a method of controlling weight gain of a mammal comprising administering to said mammal a pharmaceutically effective amount of a combination comprising an amount of a selective 5HT-2C receptor agonist and an amount of phentermine, wherein said selective 5HT-2C receptor agonist and phentermine are provided in amounts to give a synergistic effect in controlling weight gain in said mammal. For example, the invention provides a method of controlling weight gain of a mammal comprising administering to said mammal a pharmaceutically effective amount of

5 a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and/or an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in controlling weight gain in said mammal. In one embodiment, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the amount of phentermine alone are therapeutically sub-effective or ineffective in controlling weight gain in said mammal.

10 The invention further provides a method of prophylaxis or treatment of obesity, or a condition related thereto, comprising administering to a patient in need of such prophylaxis or treatment a therapeutically effective amount of a combination comprising an amount of a selective 5HT-2C receptor agonist and an amount of phentermine, wherein said selective 5HT-2C receptor agonist and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal. For example, the invention further provides a method of prophylaxis or treatment of obesity, or a condition related 15 thereto, comprising administering to a patient in need of such prophylaxis or treatment a therapeutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal.

20 In one embodiment, the amount of selective 5HT-2C receptor agonist, for example, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, alone and/or the amount of phentermine alone are therapeutically sub-effective or ineffective in decreasing food intake in said mammal. Conditions related to obesity include, for example, type II diabetes, atherosclerosis, high blood pressure, syndrome X and the like. In some embodiments the disorder is obesity.

25

The invention also provides the above disclosed methods further comprising the step of identifying a subject, said subject being in need of prophylaxis or treatment for obesity, or a condition related thereto, wherein said identifying step is performed prior to administering to said subject said therapeutically effective amount of said compounds.

30 One aspect of the present invention pertains to a method for the treatment of obesity, or a condition related thereto, comprising administering to a subject suffering from said condition a therapeutically effective amount of a composition comprising a selective 5HT-2C receptor agonist and phentermine, as described herein, preferably in the form of a pharmaceutical composition.

One aspect of the present invention pertains to a composition comprising a selective 5HT-2C receptor agonist and phentermine for use in a method of treatment of the human or animal body by therapy. For example, the invention provides a composition of the invention for use in a method of treatment of a 5HT2C disorder of the human or 5 animal body by therapy. The invention also provides a composition of the invention for use in a method of prophylaxis or treatment of obesity of a mammal, for use in a method of decreasing food intake of a mammal, for use in a method of inducing satiety in a mammal, and/or for use in a method of controlling weight gain of a mammal.

One aspect of the present invention pertains to a composition of the invention for 10 the manufacture of a medicament for use in the prophylaxis or treatment of a 5HT2C disorder of the human or animal body by therapy. For example, one aspect of the present invention pertains to a composition comprising a selective 5HT-2C receptor agonist and phentermine for the manufacture of a medicament for use in the prophylaxis or treatment of obesity, or conditions related thereto. In some embodiments the disorder is obesity. In 15 addition, for example, the invention provides a composition of the invention for the manufacture of a medicament for use in a method of decreasing food intake of a mammal, for the manufacture of a medicament for use in a method of inducing satiety in a mammal, and/or for the manufacture of a medicament for use in a method of controlling weight gain of a mammal.


20 In some embodiments, the invention provides methods for alleviation of a symptom of any of the diseases, conditions or disorders mentioned herein.

As will be recognized, the steps of the methods of the present invention need not be performed any particular number of times or in any particular sequence. Additional 25 objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are intended to be illustrative and not intended to be limiting.

### Examples

#### Synthetic Examples

30 **Example 1: (R,S) 8-Bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N-Trifluoroacetyl-3-methoxyphenethylamine*

A solution of 3-methoxyphenethylamine (10.0 g, 64.0 mmol) in dichloromethane (150 mL), was cooled to 0°C, and treated with pyridine (6.5 mL, 83.5 mmol) followed by the dropwise addition of trifluoroacetic anhydride (17.9 g, 83.5 mmol) and the resulting mixture stirred for 3 hours while warming to 20°C. The product mixture was diluted with EtOAc (500 mL), washed sequentially with 10% aqueous HCl (100 mL), water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 15.8 g of a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26 (dd, J=8, 8 Hz, 1 H), 6.81 (d, J=8 Hz, 1 H), 6.77 (d, J=8 Hz, 1 H), 6.72 (s, 1 H), 6.30 (bs, 1 H), 3.80 (s, 3 H), 3.62 (dd, J=7, 7 Hz, 2 H), 2.86 (dd, J=7, 7 Hz, 2 H). MS calculated for C<sub>11</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>2</sub>+H: 248, observed: 248.

*N-Trifluoroacetyl-2-iodo-5-methoxyphenethylamine*

A solution of N-trifluoroacetyl-3-methoxyphenethylamine (15.8 g, 64 mmol) in methanol (325 mL) was cooled to -78°C, and treated with CaCO<sub>3</sub> (14.7 g, 145 mmol), followed by a solution of ICl (29 g, 181 mmol) in methanol (40 mL). The reaction was allowed to warm to 20°C while stirring overnight and then filtered, concentrated, dissolved in EtOAc (200 mL), washed twice with 5% aqueous sodium bisulfite (100 mL), once with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 23.8 g of a white solid powder. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.68 (d, J=9 Hz, 1 H), 6.76 (s, 1 H), 6.57 (d, J=9 Hz, 1 H), 6.42 (bs, 1 H), 3.77 (s, 3 H), 3.61 (dd, J=7, 7 Hz, 2 H), 2.99 (dd, J=7, 7 Hz, 2 H). MS calculated for C<sub>11</sub>H<sub>11</sub>F<sub>3</sub>INO<sub>2</sub>+H: 374, observed: 374.

*N-Allyl, N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine*

A solution of N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (23.8 g, 63.8 mmol) in toluene (425 mL) was sequentially treated with K<sub>2</sub>CO<sub>3</sub> (12.4 g, 89.8 mmol), KOH (11.6 g, 207 mmol), n-Bu<sub>4</sub>NBr (2.2 g, 6.9 mmol) and allyl bromide (10.7 g, 89.8 mmol). The mixture was stirred at 80°C for 3.5 hours, cooled to 20°C, acidified with 10% aqueous HCl, separated and the aqueous phase extracted with ether (500 mL). The combined organic phases were washed with brine (200 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 20.5 g of a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), mixture of rotamers δ 7.67 (m, 1 H), 6.80 (m, 1 H), 6.57 (m, 1 H), 5.9-5.6 (bm, 1 H), 5.27 (m, 2 H), 4.11 (d, J=6 Hz, 0.5 H), 3.85 (d, J=6 Hz, 0.5 H), 3.77 (m, 3 H), 3.55 (m, 2 H), 3.00 (m, 2 H). MS calculated for C<sub>14</sub>H<sub>12</sub>F<sub>3</sub>INO<sub>2</sub>+H: 414, observed: 414.

*N-Trifluoroacetyl-7-methoxy-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-allyl, N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (20.5 g, 50 mmol) in dimethylformamide (250 mL) is treated with KOAc (14.6 g, 149 mmol), n-Bu<sub>4</sub>NBr (16.0 g, 50 mmol), PPh<sub>3</sub> (1.3 g, 5.0 mmol), Pd(OAc)<sub>2</sub> (0.56 g, 2.5 mmol) and stirred overnight at 90°C. The product mixture was cooled to 20°C, filtered, diluted with water (500 mL) and extracted with ether (3 x 500 mL). The combined organic phases were washed with water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 6.6 g of a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26 (d, J=8 Hz, 1 H), 6.77 (d, J=8 Hz, 1 H), 6.66 (s, 1 H), 5.34-5.19 (m, 2 H), 4.40 (m, 2 H), 3.83 (m, 2 H), 3.80 (s, 3 H), 3.00 (m, 2 H). MS calculated for C<sub>14</sub>H<sub>14</sub>F<sub>3</sub>NO<sub>2</sub>+H: 285, observed: 285.

*N-Trifluoroacetyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-7-methoxy-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine (6.6 g, 23.2 mmol) in ethanol (100 mL), was treated with 10% Pd/C (0.75 g, 2.3 mmol) and stirred overnight under an atmosphere of hydrogen. The product mixture was filtered through a pad of celite and silica and the solvent removed to give 6.27 g of a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.10 (m, 1 H), 6.74 (m, 1 H), 6.68 (m, 1 H), 4.1-3.8 (bm, 2 H), 3.8 (s, 3 H), 3.5 (m, 1.5 H), 3.4 (m, 0.5 H), 3.2-2.9 (bm, 4 H), 1.32 (m, 3 H). MS calculated for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>2</sub>+H: 288, observed: 288.

*N-Trifluoroacetyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*


A solution of N-trifluoroacetyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (1.25 g, 4.35 mmol) in acetonitrile (40 mL) was treated with N-bromosuccinimide (0.852 g, 4.79 mmol) and stirred overnight at 20°C. The product mixture was diluted with EtOAc (200 mL), washed with saturated aqueous sodium bisulfite (100 mL) and brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 1.55 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.34 (s, 1 H), 6.65 (m, 1 H), 3.87 (s, 3 H), 3.81 (m, 1 H), 3.55 (m, 1.3 H), 3.37 (m, 0.7 H), 3.2-2.9 (bm, 4 H), 1.30 (m, 3 H). MS calculated for C<sub>14</sub>H<sub>15</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 366, observed: 366.

*8-Bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-

5           1*H*-3-benzazepine (0.95 g, 2.59 mmol) in methanol (20 mL) was treated with 15% aqueous NaOH (25 mL), and stirred overnight at 20°C. The product mixture was diluted with water (100 mL), extracted twice with EtOAc (100 mL), the combined organic phases were washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.687 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (s, 1 H), 6.34 (s, 1 H), 3.87 (s, 3 H), 3.1-2.9 (m, 6 H), 2.75 (m, 1 H), 2.60 (bs, 1 H), 1.31 (d, J=7 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>16</sub>BrNO+H: 270, observed: 270.

10           **Example 2: (R,S) 8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




*N*-Trifluoroacetyl-8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

15           A solution of *N*-trifluoroacetyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.900 g, 2.67 mmol) in acetonitrile (30 mL) was treated with *N*-chlorosuccinimide (0.357 g, 2.67 mmol) and stirred overnight at 70°C. The product mixture was diluted with water (100 mL), extracted twice with EtOAc (100 mL), the combined organic phases washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (20% EtOAc in hexane, silica) resulted in 0.399 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.17 (s, 1 H), 6.68 (m, 1 H), 3.88 (s, 3 H), 3.78 (m, 1 H), 3.6-3.3 (m, 2 H), 3.2-2.9 (m, 4 H), 1.34 (m, 3 H). MS calculated for C<sub>14</sub>H<sub>15</sub>ClF<sub>3</sub>NO<sub>2</sub>+H: 322, observed: 322.

8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


25           A solution of *N*-trifluoroacetyl-8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.399 g, 1.24 mmol) in methanol (20 mL) was treated with 15% aqueous NaOH (20 mL), and stirred overnight at 20°C. The product mixture was diluted with water (100 mL), extracted twice with EtOAc (100 mL), the combined organic phases were washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.306 g of a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.05 (s, 1 H), 6.59 (s, 1 H), 3.80 (s, 3 H), 3.0-2.8 (m, 6 H), 2.62 (m, 1 H), 2.16 (bs, 1 H), 1.24 (d, J=7 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>16</sub>ClNO+H: 226, observed: 226.

**Example 3: (R,S) 8-Iodo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N*-Trifluoroacetyl-8-*ido*-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

5 A solution of *N*-trifluoroacetyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (1.50 g, 5.22 mmol) in methanol (70 mL) was treated with CaCO<sub>3</sub> (1.06 g, 10.44 mmol) followed by a solution of ICl (1.70 g, 10.44 mmol) in methanol (10 mL), and stirred overnight at 20°C. The product mixture was filtered, concentrated, dissolved in EtOAc (200 mL), extracted twice with 5% aqueous sodium bisulfite (100 mL), once with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc 10 in hexane, silica) resulted in 1.54 g of a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.55 (m, 1 H), 6.57 (m, 1 H), 3.86 (s, 3 H), 3.80 (m, 1 H), 3.60-3.30 (m, 2 H), 3.20-2.80 (m, 4 H), 1.30 (m, 3 H). MS calculated for C<sub>14</sub>H<sub>15</sub>F<sub>3</sub>INO<sub>2</sub>+H: 414, observed: 414.

15 *8-Iodo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

A solution of *N*-trifluoroacetyl-8-*ido*-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.600 g, 1.45 mmol) in methanol (20 mL) was treated with 15% aqueous NaOH (20 mL), and stirred for 3 hours at 50°C. The product mixture was diluted with water (100 mL), extracted twice with EtOAc (100 mL), the combined organic phases were 20 washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.425 g of a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52 (s, 1 H), 6.57 (s, 1 H), 3.86 (s, 3 H), 3.12-3.06 (m, 4 H), 2.95 (m, 2 H), 2.75 (m, 1 H), 2.43 (bs, 1 H), 1.33 (d, J=8 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>16</sub>INO+H: 318, observed: 318.

25 **Example 4: (R,S) 8-Bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N*-Trifluoroacetyl-8-*bromo*-7-*hydroxy*-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


30 A solution of *N*-trifluoroacetyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (1.50 g, 4.10 mmol) in dichloromethane (80 mL) was treated dropwise with BBr<sub>3</sub> (9.4 mL of a 1.0M solution in CH<sub>2</sub>Cl<sub>2</sub>, 9.4 mmol), and the mixture stirred

overnight while warming to 20°C. The excess BBr<sub>3</sub> was quenched with the dropwise addition of water, the mixture diluted with ether (200 mL), washed with Na<sub>2</sub>CO<sub>3</sub> (100 mL) and brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 1.25 g of a white solid foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.25 (s, 1 H), 6.79 (m, 1 H), 3.79 (m, 1 H), 3.7-3.3 (m, 2 H), 3.2-2.8 (m, 4 H), 1.32 (m, 3 H).

*8-Bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

10 A solution of N-trifluoroacetyl-8-bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.655 g, 1.89 mmol) in methanol (20 mL) was treated with 15% aqueous NaOH (20 mL), and stirred overnight at 20°C. The product mixture was diluted with water (100 mL), extracted twice with EtOAc (100 mL), the combined organic phases were washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.460 g of a clear oil. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.11 (s, 1 H), 6.65 (s, 1 H), 2.90 (m, 1 H), 15 2.73 (m, 5 H), 2.55 (m, 1 H), 1.19 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>14</sub>BrNO+H: 256, observed: 256.

**Example 5: (R,S) 7-Allyloxy-8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**



20 *N-Trifluoroacetyl-7-allyloxy-8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.150 g, 0.426 mmol) in dichloromethane (5 mL) was treated with allyl bromide (0.155 g, 1.28 mmol) and DBU (0.195 g, 1.28 mmol) and then stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (50 mL), washed with 5% aqueous HCl (20 mL), brine (20 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.149 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.34 (s, 1 H), 6.65 (m, 1 H), 6.04 (m, 1 H), 5.47 (d, J=17 Hz, 1 H), 5.30 (d, J=9 Hz, 1 H), 4.59 (s, 2 H), 3.80 (m, 1 H), 3.6-3.3 (m, 3 H), 3.2-2.8 (m, 4 H), 1.31 (m, 3 H). MS calculated for C<sub>16</sub>H<sub>17</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 392, observed: 392.


30

*7-Allyloxy-8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-7-allyloxy-8-bromo-1-methyl-2,3,4,5-tetrahydro-

5 *1H-3-benzazepine* (1.18 g, 3.00 mmol) in methanol (35 mL) was treated with 15% aqueous NaOH (35 mL), and stirred overnight at 20°C. The product mixture was diluted with water (200 mL), extracted twice with EtOAc (200 mL), the combined organic phases were washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.880 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (s, 1 H), 6.63 (s, 1 H), 6.04 (m, 1 H), 5.47 (d, J=17 Hz, 1 H), 5.29 (d, J=11 Hz, 1 H), 4.58 (s, 2 H), 3.01 (m, 3 H), 2.89 (m, 3 H), 2.75 (m, 1 H), 1.31 (d, J=7 Hz, 3 H). MS calculated for C<sub>14</sub>H<sub>18</sub>BrNO<sub>2</sub>+H: 296, observed: 296.

10 **Example 6: (R,S) 7-Benzyl-8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-Trifluoroacetyl-7-benzyl-8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

15 A solution of *N*-trifluoroacetyl-8-bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.075 g, 0.213 mmol) in dichloromethane (5 mL) was treated with benzyl bromide (0.072 g, 0.64 mmol), DBU (0.100 g, 0.64 mmol), and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (50 mL), washed with 5% aqueous HCl (20 mL), brine (20 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.081 g of a clear oil. MS calculated for C<sub>20</sub>H<sub>19</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 442, observed: 442.


20

*7-Benzyl-8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

25 A solution of *N*-trifluoroacetyl-7-benzyl-8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.81 g, 1.83 mmol) in methanol (20 mL) was treated with 15% aqueous NaOH (20 mL), and stirred overnight at 20°C. The product mixture was diluted with water (200 mL), extracted twice with EtOAc (200 mL), the combined organic phases were washed with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.412 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (d, J=8 Hz, 2 H), 7.30 (dd, J=7, 8 Hz, 2 H), 7.23 (m, 2 H), 6.61 (s, 1 H), 5.03 (s, 2 H), 2.94 (m, 3 H), 2.81 (m, 3 H), 2.62 (m, 1 H), 2.30 (bs, 1 H), 1.24 (d, J=7 Hz, 3 H). MS calculated for C<sub>18</sub>H<sub>20</sub>BrNO<sub>2</sub>+H: 346, observed:

30

346.

**Example 7: (R,S) 8-Bromo-7-ethoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N*-Trifluoroacetyl-8-bromo-7-ethoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


5 A solution of *N*-trifluoroacetyl-8-bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.015 g, 0.043 mmol) in dichloromethane (1 mL) was treated with ethyl iodide (0.016 g, 0.102 mmol), DBU (0.016 g, 0.102 mmol) and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with 5% aqueous HCl (5 mL), brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.010 g of a clear oil.

10

*8-Bromo-7-ethoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

15 A solution of *N*-trifluoroacetyl-8-bromo-7-ethoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.010 g, 0.026 mmol) in methanol (1 mL) was treated with 15% aqueous NaOH (1 mL), and stirred overnight at 20°C. The product mixture was diluted with water (3 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (3 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.007 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (s, 1 H), 6.63 (s, 1 H), 4.07 (q, J=6 Hz, 2 H), 3.03 (m, 3 H), 2.91 (m, 3 H), 2.73 (m, 1 H), 2.26 (bs, 1 H), 1.46 (t, J=6 Hz, 3 H), 1.32 (d, J=7 Hz, 3 H). MS calculated for C<sub>15</sub>H<sub>17</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 380, observed: 380.

20

**Example 8: (R,S) 8-Bromo-7-isopropoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N*-Trifluoroacetyl-8-bromo-7-isopropoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


25 A solution of *N*-trifluoroacetyl-8-bromo-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.035 g, 0.099 mmol) in dichloromethane (1 mL) was treated with isopropyl bromide (0.037 g, 0.297 mmol), DBU (0.048 g, 0.205 mmol) and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with 5% aqueous HCl (5 mL), brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.014 g of a clear oil. MS calculated for

$C_{16}H_{19}BrF_3NO_2 + H: 394$ , observed: 394.

**8-Bromo-7-isopropoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**

5 A solution of N-trifluoroacetyl-8-bromo-7-isopropoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.014 g, 0.035 mmol) in methanol (1 mL) was treated with 15% aqueous NaOH (1 mL), and stirred overnight at 20°C. The product mixture was diluted with water (3 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (3 mL), dried with  $Na_2SO_4$  and concentrated to give 0.008 g of a clear oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.24 (s, 1 H), 6.64 (s, 1 H), 4.48 (m, 1 H), 10 2.98 (m, 3 H), 2.87 (m, 3 H), 1.36 (m, 6 H), 1.30 (d,  $J=7$  Hz, 3 H). MS calculated for  $C_{14}H_{20}BrNO + H: 298$ , observed: 298.


**Example 9: (R,S) N-Methyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**



A solution of 8-Bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (6 mg, 0.022 mmol) in methanol (1 mL) was treated with excess paraformaldehyde, 1.0 M HCl in ether (0.004 mL, 0.004 mmol),  $NaBH_3CN$  (1.0 mg, 0.013 mmol), and stirred overnight at 20°C. The product mixture was diluted with 5% aqueous NaOH (5 mL), extracted 3 times with  $CH_2Cl_2$  (5 mL each), the combined organic phases were dried with  $Na_2SO_4$  and concentrated. Flash chromatography (10% MeOH in  $CH_2Cl_2$ , silica) resulted in 5 mg of a clear oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.31 (s, 1 H), 6.66 (s, 1 H), 3.87 (s, 3 H), 3.26 (bm, 2 H), 3.01 (bs, 1 H), 2.85 (m, 2 H), 2.45 (s, 3 H), 2.45-2.25 (m, 2 H), 1.36 (d,  $J=7$  Hz, 3 H). MS calculated for  $C_{13}H_{18}BrNO + H: 284$ , observed: 284.

25


**Example 10: (R,S) N-Propyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**



30 A solution of 8-Bromo-7-methoxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine (6 mg, 0.022 mmol) in methanol (1 mL) was treated with propionaldehyde (5.0 mg, 0.067

5 mmol), 1.0 M HCl in ether (0.004 mL, 0.004 mmol), NaBH<sub>3</sub>CN (1.0 mg, 0.013 mmol), and stirred overnight at 20°C. The product mixture was diluted with 5% aqueous NaOH (5 mL), extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> (5 mL each), the combined organic phases were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, silica) resulted in 4 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.33 (s, 1 H), 6.87 (s, 1 H), 3.84 (s, 3 H), 3.25 (m, 2 H), 3.11 (m, 2 H), 2.97 (m, 1 H), 2.78 (bm, 2 H), 2.63 (bm, 2 H), 1.67 (m, 2 H), 1.38 (d, J=7 Hz, 3 H), 0.96 (t, J=7 Hz, 3 H). MS calculated for C<sub>15</sub>H<sub>22</sub>BrNO+H: 312, observed: 312.

10 **Example 11: (R,S) 7-Hydroxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




*N*-Trifluoroacetyl-7-hydroxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

15 A solution of *N*-trifluoroacetyl-8-iodo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (80 mg, 0.19 mmol) in dichloromethane (3 mL) was treated with BBr<sub>3</sub> (0.40 mL of a 1.0M solution in CH<sub>2</sub>Cl<sub>2</sub>, 0.40 mmol) and stirred overnight at 20°C. The excess BBr<sub>3</sub> was quenched with water and the product mixture was diluted with ether (20 mL), washed with Na<sub>2</sub>CO<sub>3</sub> (10 mL) and brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 74 mg of a white solid. MS calculated for C<sub>13</sub>H<sub>12</sub>F<sub>3</sub>INO<sub>2</sub>+H: 400, observed: 400.

20 *7-Hydroxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

25 A solution of *N*-trifluoroacetyl-7-hydroxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (25 mg, 0.063 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 13 mg of a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.46 (s, 1 H), 6.64 (s, 1 H), 3.16 (m, 3 H), 2.94 (m, 3 H), 2.81 (m, 1 H), 1.35 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>14</sub>INO+H: 304, observed: 304.

30

**Example 12: (R,S) 7-Allyloxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N*-Trifluoroacetyl-7-allyloxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


A solution of *N*-trifluoroacetyl-7-hydroxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (30 mg, 0.075 mmol) in dichloromethane (2 mL) was treated with allyl bromide (18 mg, 0.15 mmol), DBU (23 mg, 0.15 mmol) and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with 5% aqueous HCl (5 mL), brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 23 mg of a clear oil. MS calculated for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>INO<sub>2</sub>+H: 440, observed: 440.

10

7-Allyloxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of *N*-trifluoroacetyl-7-allyloxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (23 mg, 0.058 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 18 mg of a white solid. MS calculated for C<sub>14</sub>H<sub>18</sub>INO+H: 344, observed: 344.

20

**Example 13: (R,S) 3,5-Dimethyl-6,7,8,9-tetrahydro-5*H*-1-oxa-7-aza-cycloheptaindene***N*-trifluoroacetyl-3,5-dimethyl-6,7,8,9-tetrahydro-5*H*-1-oxa-7-aza-cycloheptaindene

A solution of *N*-trifluoroacetyl-7-allyloxy-8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (158 mg, 0.360 mmol) in dimethylformamide (4 mL) was treated with KOAc (106 mg, 1.08 mmol), *n*-Bu<sub>3</sub>NBr (116 mg, 0.360 mmol), PPh<sub>3</sub> (13 mg, 0.036 mmol), Pd(OAc)<sub>2</sub> (4 mg, 0.018 mmol) and stirred overnight at 100°C. The product mixture was filtered, water (10 mL) added and then extracted twice with EtOAc (10 mL). The combined organic phases were washed with brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (5% EtOAc in hexane, silica) resulted in 15 mg of a

25


30

clear oil. MS calculated for  $C_{16}H_{16}F_3NO_2+H$ : 312, observed: 312.

**3,5-Dimethyl-6,7,8,9-tetrahydro-5H-1-oxa-7-aza-cycloheptaindene**

5 A solution of N-trifluoroacetyl-3,5-dimethyl-6,7,8,9-tetrahydro-5H-1-oxa-7-aza-cycloheptaindene (15 mg, 0.048 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with  $Na_2SO_4$  and concentrated to give 10 mg of a white solid.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.25 (s, 1 H), 7.12 (s, 1 H), 7.09 (s, 1 H), 3.12 (m, 1 H), 2.97 (m, 4 H), 2.85 (m, 1 H), 2.64 (bm, 1 H), 2.15 (s, 3 H), 1.34 (d,  $J=8$  Hz, 3 H). MS calculated for  $C_{14}H_{17}NO+H$ : 216, observed: 216.

**Example 14: (R,S) 7-Allyloxy-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**



15 *N*-Trifluoroacetyl-8-chloro-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine


A solution of N-trifluoroacetyl-8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (48 mg, 0.15 mmol) in dichloromethane (2 mL) was treated with  $BBr_3$  (0.30 mL of a 1.0M solution in  $CH_2Cl_2$ , 0.30 mmol) and stirred overnight at 20°C. The excess  $BBr_3$  was quenched with water and the resulting mixture diluted with ether (20 mL), washed with  $Na_2CO_3$  (10 mL) and brine (10 mL), dried with  $Na_2SO_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 24 mg of a white solid. MS calculated for  $C_{13}H_{13}ClF_3NO_2+H$ : 308, observed: 308.

25 *N*-Trifluoroacetyl-7-allyloxy-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine

A solution of N-trifluoroacetyl-8-chloro-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (24 mg, 0.078 mmol) in dichloromethane (2 mL) was treated with allyl bromide (18 mg, 0.15 mmol), DBU (23 mg, 0.15 mmol) and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with 5% aqueous HCl (5 mL), brine (5 mL), dried with  $Na_2SO_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 23 mg of a white solid. MS calculated for  $C_{16}H_{17}ClF_3NO_2+H$ : 348, observed: 348.

*7-Allyloxy-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-7-allyloxy-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (23 mg, 0.066 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 19 mg of a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.12 (s, 1 H), 6.81 (s, 1 H), 6.03 (m, 1 H), 5.43 (d, J=17 Hz, 1 H), 5.24 (d, J=10 Hz, 1 H), 4.57 (d, J=5 Hz, 2 H), 3.1-2.9 (m, 5 H), 2.81 (m, 1 H), 2.63 (m, 1 H), 1.30 (d, J=7 Hz, 3 H).

**Example 15: (R,S) 7-Methoxy-1-methyl-8-(2-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine**

*N*-Trifluoroacetyl-7-methoxy-1-methyl-8-(2-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine


A solution of N-trifluoromethylacetyl-8-bromo-7-methoxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine (51 mg, 0.14 mmol) in 1,4-dioxane (2 mL) was treated with thiophene-2-boronic acid (36 mg, 0.28 mmol), K<sub>2</sub>CO<sub>3</sub> (58 mg, 0.42 mmol), water (0.1 mL), Pd(PPh<sub>3</sub>)<sub>4</sub> (16 mg, 0.014 mmol) and stirred overnight at 100°C. The product mixture was diluted with EtOAc, filtered, absorbed on silica and purified by flash chromatography (10% EtOAc in hexane, silica) resulting in 28 mg of a yellow solid. MS calculated for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>2</sub>S+H: 370, observed: 370.

*7-Methoxy-1-methyl-8-(2-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-7-methoxy-1-methyl-8-(2-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (28 mg, 0.076 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred 0.5 hours at 50°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 18 mg of a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45 (d, J=4 Hz, 1 H), 7.39 (s, 1 H), 7.27 (d, J=6 Hz, 1 H), 7.07 (dd, J=4, 6 Hz, 1 H), 6.71 (s, 1 H), 3.90 (s, 3 H), 3.1-2.9 (m, 6 H), 2.80 (m, 1 H), 2.22 (bs, 1 H), 1.38 (d, J=7 Hz, 3 H). MS calculated for C<sub>18</sub>H<sub>19</sub>NOS+H:

274, observed: 274.

**Example 16: (R,S) 8-Cyano-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




*N*-Trifluoroacetyl-8-cyano-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of *N*-trifluoroacetyl-8-bromo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (18 mg, 0.05 mmol) in dimethylformamide (1 mL) was treated with CuCN (20 mg, 0.24 mmol) and the mixture was microwaved at 200°C for 0.5 hours. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (35% EtOAc in hexane, silica) resulted in 10 mg of a clear oil. MS calculated for C<sub>15</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>+H: 313, observed: 313.

15      *8-Cyano-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of *N*-trifluoroacetyl-8-cyano-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (10 mg, 0.032 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred 1 hour at 50°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 6.0 mg of a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.33 (s, 1 H), 6.93 (s, 1 H), 3.91 (s, 3 H), 3.18-2.97 (m, 5 H), 2.80 (m, 1 H), 2.60 (m, 1 H), 1.33 (d, J=8 Hz, 3 H). MS calculated for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>+H: 217, observed: 217.

25      **Example 17: (R,S) 8-bromo-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-Trifluoroacetyl-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of diethyl zinc (1 mL, 1 M in hexanes) in dichloromethane (1 mL) at 0°C was treated with trifluoroacetic acid in dichloromethane (0.5 mL) and the mixture

stirred for 15 min. Diiodomethane (0.280 g, 1.0 mmol) in dichloromethane (0.5 mL) was then added and stirred for 15 minutes. N-Trifluoroacetyl-7-methoxy-1-methylene-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.075 g, 0.26 mmol) in dichloromethane (1 mL) was added and the mixture stirred for 30 minutes at 0°C and then for 2 hours at 20°C. The product 5 mixture was quenched with aqueous saturated NH<sub>4</sub>Cl (5 mL), extracted twice with CH<sub>2</sub>Cl<sub>2</sub> (20 mL), washed with saturated aqueous NaHCO<sub>3</sub> (10 mL), washed with H<sub>2</sub>O (10 mL), and concentrated. Flash chromatography (7% EtOAc in hexanes, silica) resulted in 0.050 g of a white solid. MS calculated for C<sub>15</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>2</sub>+H: 300, observed: 300.

10 *N*-Trifluoroacetyl-8-bromo-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine


A solution of N-trifluoroacetyl-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.025 g, 0.08 mmol) in acetonitrile (1 mL) was treated with N-bromosuccinimide (0.032 g, 0.18 mmol) and stirred for 2 hrs. at 50°C. The product 15 mixture was concentrated and then purified by flash chromatography (10% EtOAc in hexanes, silica) resulting in 0.014 g of a white solid. MS calculated for C<sub>15</sub>H<sub>15</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 378, observed: 378.

20 *8-bromo-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-bromo-1-cyclopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.014 g, 0.037 mmol) in methanol (1 mL) was treated with 15% aqueous NaOH (1 mL), and stirred for 2 hours at 50°C. The product mixture was diluted with brine (10 mL), extracted twice with EtOAc (10 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.008 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.26 (s, 1 H), 6.78 (s, 1 H), 3.83 (s, 3 H), 3.02 (m, 2 H), 2.92 (m, 2 H), 2.67 (s, 2 H), 0.91 (m, 2 H), 0.85 (m, 2 H). MS calculated for C<sub>15</sub>H<sub>16</sub>BrNO+H: 282, observed: 282.

25 **Example 18: (R,S) 8-bromo-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**

30



*N*-Trifluoroacetyl-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of N-trifluoroacetyl-7-methoxy-1-methylene-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.100 g, 0.35 mmol) in tetrahydrofuran (1 mL) was treated with BH<sub>3</sub>-THF complex (0.36 mL, 1 M in THF), and stirred for 30 min. at 20°C. Water (0.5 mL), 5 saturated aqueous NaHCO<sub>3</sub> (0.5 mL), and 30% H<sub>2</sub>O<sub>2</sub> (0.2 mL) were added sequentially and the reaction stirred for 30 min. at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with brine (10 mL), and concentrated. Flash chromatography (33% EtOAc in hexane, silica) resulted in 0.035 g of a clear oil. MS calculated for C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>3</sub>+H: 304, observed: 304.

10

*N*-Trifluoroacetyl-8-bromo-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine


A solution of N-trifluoromethylacetyl-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.035 g, 0.12 mmol) in acetonitrile (1 mL) was treated with N-bromosuccinimide (0.025 g, 0.14 mmol), and stirred for 30 min. at 20°C. The product mixture was concentrated and then purified by flash chromatography (33% EtOAc in hexane, silica) resulting in 0.019 g clear oil. MS calculated for C<sub>14</sub>H<sub>15</sub>BrF<sub>3</sub>NO<sub>3</sub>+H: 382, observed: 382.

15

8-bromo-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of N-trifluoroacetyl-8-bromo-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.009 g, 0.024 mmol) in methanol (1 mL) was treated with 15% aqueous NaOH (1 mL), and stirred for 1 hour at 50°C. The product mixture was diluted with brine (5 mL), extracted twice with EtOAc (5 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.006 g clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28 (s, 1 H), 6.79 (s, 1 H), 3.84 (m, 2 H), 3.0-2.8 (m, 7 H). MS calculated for C<sub>12</sub>H<sub>16</sub>BrNO<sub>2</sub>+H: 286, observed: 286.

20

30 Example 19: (R,S) 8-Bromo-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine

*N-Crotyl, N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine*

5 A solution of N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (6.68 g, 17.9 mmol) in toluene (100 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (3.22 g, 23.3 mmol), KOH (3.01 g, 53.7 mmol), n-Bu<sub>4</sub>NBr (0.580 g, 1.80 mmol) and crotyl bromide (3.15 g, 23.3 mmol). The mixture was stirred at 75°C for 16 hours, cooled to 20°C, diluted with Et<sub>2</sub>O (500 mL), washed with 10% aqueous HCl (500 mL) and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 5.22 g of a clear oil. MS calculated for C<sub>15</sub>H<sub>17</sub>F<sub>3</sub>INO<sub>2</sub>+H: 428, observed: 428.

10 *N-Trifluoroacetyl-1-ethylene-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

15 A solution of N-crotyl, N-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (5.20 g, 12.2 mmol) in dimethylformamide (80 mL) was treated with KOAc (3.59 g, 36.6 mmol), n-Bu<sub>4</sub>NBr (3.93 g, 12.2 mmol), PPh<sub>3</sub> (0.320 g, 1.22 mmol), Pd(OAc)<sub>2</sub> (0.137 g, 0.61 mmol) and stirred overnight at 90°C. The product mixture was cooled to 20°C, diluted with water (200 mL), extracted twice with ether (500 mL), the combined organic phases washed twice with brine (200 mL), and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 2.29 g of a clear oil, which consists of a mixture of olefinic isomers. MS calculated for C<sub>15</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>2</sub>+H: 300, observed: 300.

20 *N-Trifluoroacetyl-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*


25 A solution of N-trifluoroacetyl-1-ethylene-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (2.29 g, 7.65 mmol) in methanol (100 mL) was treated with 10% Pd/C (4.0 g, 0.77 mmol)) and stirred overnight under an atmosphere of hydrogen. The product mixture was filtered through a pad of celite and silica, and the solvent removed to give 2.14 g of a clear oil. MS calculated for C<sub>15</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>2</sub>+H: 302, observed: 302.

*N-Trifluoroacetyl-8-bromo-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

30 A solution of N-trifluorolacetyl-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (0.710 g, 2.36 mmol) in acetonitrile (20 mL) was treated with N-bromosuccinimide (0.504 g, 2.83 mmol), and stirred overnight at 20°C. The product mixture was concentrated, diluted with EtOAc (100 mL), washed with water (50 mL) and brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% EtOAc in hexanes, silica) resulted in 0.561 g of a clear oil. MS calculated for C<sub>15</sub>H<sub>17</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 380, observed: 380.

*8-Bromo-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-bromo-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (0.561 g, 1.48 mmol) in methanol (30 mL) was treated with 15% aqueous 5 NaOH (30 mL), and stirred overnight at 20°C. The product mixture was diluted with brine (100 mL), extracted twice with EtOAc (200 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.412 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.24 (s, 1 H), 6.76 (s, 1 H), 3.83 (s, 3 H), 3.02 (m, 3 H), 2.91 (s, 1 H), 2.85-2.76 (m, 3 H), 2.63 (m, 1 H), 1.78 (m, 1 H), 1.72 (m, 1 H), 0.94 (dd, J=8, 8 Hz, 3 H). MS calculated for 10 C<sub>13</sub>H<sub>18</sub>BrNO+H: 284, observed: 284.


**Example 20: (R,S) 8-Chloro-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine***N-Trifluoroacetyl-8-chloro-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluorolacetyl-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-15 benzazepine (0.600 g, 1.99 mmol) in acetonitrile (20 mL) was treated with N-chlorosuccinimide (0.057 g, 0.32 mmol), and stirred overnight at 60°C. The product mixture was concentrated, diluted with EtOAc (100 mL), washed with water (50 mL) and brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% EtOAc 20 in hexanes, silica) resulted in 0.421 g of a clear oil. MS calculated for C<sub>13</sub>H<sub>17</sub>ClF<sub>3</sub>NO<sub>2</sub>+H: 336, observed: 336.

*8-Chloro-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-chloro-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1H-25 benzazepine (0.421 g, 1.25 mmol) in methanol (30 mL) was treated with 15% aqueous NaOH (30 mL), and stirred overnight at 20°C. The product mixture was diluted with brine (100 mL), extracted twice with EtOAc (200 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.241 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.05 (s, 1 H), 6.79 (s, 1 H), 3.84 (s, 3 H), 3.03 (m, 3 H), 2.91 (s, 1 H), 2.86-2.76 (m, 3 H), 2.64 (m, 1 H), 30 1.81 (m, 1 H), 1.72 (m, 1 H), 0.93 (dd, J=8, 8 Hz, 3 H). MS calculated for C<sub>13</sub>H<sub>18</sub>ClNO+H: 240, observed: 240.

**Example 21: (R,S) 8-Bromo-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-(3-methylbut-2-enyl), *N*-trifluoroacetyl-2-iodo-5-methoxyphenethylamine

5 A solution of *N*-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (0.700 g, 1.88 mmol) in toluene (25 mL) was treated with  $\text{K}_2\text{CO}_3$  (0.340 g, 2.4 mmol), KOH (0.210 g, 3.76 mmol), *n*-Bu<sub>4</sub>NBr (0.060 g, 0.19 mmol) and 4-bromo-2-methyl-2-butene (0.364 g, 2.44 mmol). The mixture was stirred at 80°C for 3 hours, cooled to 20°C, diluted with ether (100 mL), washed with 10% HCl (50 mL) and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 0.272 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers)  $\delta$  7.65 (m, 1 H), 6.75 (m, 1 H), 6.54 (m, 1 H), 5.20 (m, 4 H), 5.0 (m, 6 H), 4.10 (m, 1 H), 3.82 (m, 1 H), 3.76 (d, 2H), 3.50 (m, 2 H), 3.02 (m, 2 H), 1.75 (m, 3 H), 1.66 (m, 3 H).

10 *N*-Trifluoroacetyl-1-isopropylene-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine

15 A solution of *N*-(3-methylbut-2-enyl), *N*-trifluoroacetyl-2-iodo-5-methoxyphenethylamine (0.0272 g, 0.62 mmol) in dimethylformamide (12 mL) was treated with KOAc (0.183 g, 1.86 mmol), *n*-Bu<sub>4</sub>NBr (0.200 g, 0.062 mmol), PPh<sub>3</sub> (0.016 g, 0.062 mmol), Pd(OAc)<sub>2</sub> (0.183 g, 1.86 mmol) and stirred overnight at 90°C. The product mixture was cooled to 20°C, diluted with water (50 mL), extracted twice with ether (50 mL), the combined organic phases were washed with brine (50 mL), and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 0.096 g of a clear oil. MS calculated for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>2</sub>+H: 314, observed: 314.

20 *N*-Trifluoroacetyl-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine


25 A solution of *N*-trifluoroacetyl-1-isopropylene-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.096 g, 0.31 mmol) in ethanol (2 mL) was treated with 10% Pd/C (0.033 g, 0.031 mmol) and stirred overnight under an atmosphere of hydrogen. The product mixture was filtered through a pad of celite and silica, and the solvent removed to give 30 0.091 g of a clear oil. MS calculated for C<sub>16</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>2</sub>+H: 316, observed: 316.

*N-Trifluoroacetyl-8-bromo-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

5 A solution of N-trifluorolactetyl-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.091 g, 0.29 mmol) in acetonitrile (3 mL) was treated with N-bromosuccinimide (0.057 g, 0.32 mmol), and stirred overnight at 20°C. After removing the solvent, flash chromatography (10% EtOAc in hexanes, silica) resulted in 0.056 g of a clear oil. MS calculated for  $C_{16}H_{19}BrF_3NO_2+H$ : 394, observed: 394.

*8-Bromo-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

10 A solution of N-trifluoroacetyl-8-bromo-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.013 g, 0.03 mmol) methanol (0.5 mL) was treated with 15% aqueous NaOH (0.5 mL), and stirred overnight at 20°C. The product mixture was diluted with brine (5 mL), extracted twice with EtOAc (5 mL), dried with  $MgSO_4$ , and concentrated to give 0.10 g of a clear oil.  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  7.08 (s, 1 H), 6.64 (s, 1 H), 3.72 (s, 3 H), 3.2-3.10 (m, 3 H), 2.7-2.5 (m, 3 H), 2.3-2.1 (m, 2 H), 0.96 (d, 15 3 H), 0.63 (d, 3 H). MS calculated for  $C_{14}H_{20}BrNO+H$ : 298, observed: 298.

**Example 22: (R,S) 8-Bromo-7-hydroxy-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine***N-Trifluoroacetyl-8-bromo-7-hydroxy-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*


20 A solution of N-trifluoroacetyl-8-bromo-1-isopropyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.041 g, 0.10 mmol) in dichloromethane (1 mL) was treated with  $BrF_3$  (0.32 mL, 1.0 M solution in  $CH_2Cl_2$ ) and stirred overnight at 20°C. The excess  $BrF_3$  was quenched with water and the resulting mixture diluted with ether (50 mL), washed twice with saturated aqueous  $Na_2CO_3$  (20 mL) and concentrated. Flash chromatography (20% EtOAc in hexanes, silica) resulted in 0.037 g clear oil. MS calculated for  $C_{15}H_{17}BrF_3NO_2+H$ : 380, observed: 380.

*8-Bromo-7-hydroxy-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

30 A solution of N-trifluoroacetyl-8-bromo-7-hydroxy-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.018 g, 0.047 mmol) in methanol (1 mL) was treated with 15%

5 aqueous NaOH (1 mL), and stirred for 3 hours at 50°C. The product mixture was brought to pH 7-8 with 10% aqueous HCl, extracted three times with EtOAc (50 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.013 g of a white solid. <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD) δ 7.10 (s, 1 H), 6.60 (s, 1 H), 3.30 (m, 1H), 3.2-3.0 (m, 2 H), 2.78 (m, 1H), 2.7-2.5 (m, 2H), 2.3-2.1 (m, 2 H), 1.05 (d, 3 H), 0.73 (d, 3 H). MS calculated for C<sub>13</sub>H<sub>18</sub>BrNO+H: 284, observed: 284.

**Example 23: (R,S) 7-Allyloxy-8-bromo-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



10

*N*-Trifluoroacetyl-7-allyloxy-8-bromo-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

15

A solution of *N*-trifluoroacetyl-8-bromo-7-hydroxy-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.017 g, 0.045 mmol) in dichloromethane (1 mL) was treated with N<sup>””</sup>-tert-butyl-N, N, N<sup>’</sup>, N<sup>’</sup>, N<sup>””</sup>-hexamethylphosphorimidic triamide (0.016 g, 0.068 mmol), allyl bromide (0.011 g, 0.09 mmol) and stirred for 3 hours at 20°C. The product mixture was diluted with 10% aqueous HCl, extracted twice with dichloromethane (20 mL), and concentrated. Flash chromatography (10% EtOAc in hexanes, silica) resulted in 0.011 g of a clear oil. MS calculated for C<sub>18</sub>H<sub>21</sub>BrF<sub>3</sub>NO<sub>2</sub>+H: 420, observed: 420.


20

7-Allyloxy-8-bromo-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

25

A solution of *N*-trifluoroacetyl-7-allyloxy-8-bromo-1-isopropyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.011 g, 0.026 mmol) in methanol (0.5 mL) was treated with of 15% aqueous NaOH (0.5 mL), and stirred for 3 hours at 50°C. The product mixture was diluted with brine (5 mL), extracted twice with EtOAc (5 mL), dried with MgSO<sub>4</sub>, and concentrated to give 0.010 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.09 (s, 1 H), 6.62 (s, 1 H), 5.94 (m, 1 H), 5.32 (dd, 1 H), 5.12 (dd, 1H), 4.46 (d, 2H), 3.19 (m, 1 H), 3.05 (m, 2 H), 2.66 (m, 1 H), 2.5 (bm, 2 H), 2.3-2.1 (m, 2 H), 0.95 (d, 3 H), 0.63 (d, 3 H). MS calculated for C<sub>16</sub>H<sub>22</sub>BrNO+H: 324, observed: 324.

30

**Example 24: 8-Bromo-7-methoxy-1,4-dimethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*****N*-Trifluoroacetyl-1-(3-methoxyphenyl)-2-propylamine**

5 A solution of 1-(3-methoxyphenyl)-2-propylamine (3.59 g, 21.7 mmol) in dichloromethane (75 mL) at 0°C, was treated with pyridine (2.1 mL, 28.2 mmol), trifluoracetic anhydride (5.9 g, 28.2 mmol), and then stirred for 3 hours while warming to 20°C. The product mixture was diluted with EtOAc (300 mL), washed sequentially with 10% aqueous HCl (100 mL), water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (20% EtOAc in hexane, silica) resulted in 4.29 g of a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.17 (dd, J=8, 8 Hz, 1 H), 6.76 (m, 3 H), 4.19 (m, 1 H), 3.77 (s, 3 H), 2.78 (m, 2 H), 1.21 (d, J=7 Hz, 2 H).

10

***N*-Trifluoroacetyl-1-(2-iodo-5-methoxyphenyl)-2-propylamine**

15 A solution of N-trifluoroacetyl-1-(3-methoxyphenyl)-2-propylamine (4.29 g, 15.7 mmol) in methanol (100 mL) was cooled to -78°C and treated with CaCO<sub>3</sub> (3.17 g, 31.4 mmol), followed by a solution of ICl (6.37 g, 39.3 mmol) in methanol (50 mL). The reaction was allowed to warm to 20°C while stirring overnight. The product mixture was filtered, concentrated, dissolved in EtOAc (200 mL), washed twice with 5% aqueous sodium bisulphite (100 mL), once with brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give 6.72 g of a white solid powder. MS calculated for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>INO<sub>2</sub>+H: 388, observed: 388.

20

***N*-Allyl, *N*-trifluoroacetyl-1-(2-iodo-5-methoxyphenyl)-2-propylamine**

25 A solution of N-trifluoroacetyl-1-(2-iodo-5-methoxyphenyl)-2-propylamine (6.09 g, 15.7 mmol) in toluene (450 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (2.82 g, 20.4 mmol), KOH (2.45 g, 47.1 mmol), n-Bu<sub>4</sub>NBr (0.506 g, 1.57 mmol) and allyl bromide (2.47 g, 20.4 mmol), and stirred overnight at 80°C. The product mixture was acidified with 10% aqueous HCl, separated, the aqueous phase extracted with ether (500 mL), the combined organic phases were washed with brine (200 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 4.45 g of a brown oil.

30

*N-Trifluoroacetyl-7-methoxy-4-methyl-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-allyl, N-trifluoroacetyl-1-(2-iodo-5-methoxyphenyl)-2-propylamine (4.45 g, 10.8 mmol) in dimethylformamide (120 mL) was treated with KOAc (3.17 g, 32.3 mmol), n-Bu<sub>4</sub>NBr (3.47 g, 10.8 mmol), PPh<sub>3</sub> (0.283 g, 1.08 mmol),

5 Pd(OAc)<sub>2</sub> (0.242 g, 1.08 mmol) and stirred overnight at 80°C. The product mixture was cooled to 20°C, filtered, diluted with water (200 mL), extracted with ether (3 x 200 mL), the combined organic phases washed with water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 1.39 g of a yellow oil.

10

*N-Trifluoroacetyl-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-7-methoxy-4-methyl-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine (1.39 g, 4.64 mmol) in ethanol (40 mL) was treated with 10% Pd/C (0.49 g, 0.46 mmol) and stirred overnight under an atmosphere of hydrogen.

15

The product mixture was filtered through a pad of celite and silica and then concentrated. Flash chromatography (20% EtOAc in hexane, silica) resulted in 0.77 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.06 (m, 1 H), 6.71 (m, 1 H), 6.63 (m, 1 H), 4.38 (bm, 1 H), 3.8 (s, 3H), 3.6 (m, 1 H), 3.25 (m, 1 H), 3.18 (bm, 2 H), 2.72 (m, 1 H), 1.34 (m, 3 H) 1.22 (m, 3 H).

20

*N-Trifluoroacetyl-8-bromo-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution N-trifluoroacetyl-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (0.452 g, 1.50 mmol) in acetonitrile (20 mL) was treated with N-bromosuccinimide (0.294 g, 1.65 mmol) and stirred overnight at 20°C. The product mixture was diluted with EtOAc (100 mL), washed with sodium bisulfite (50 mL) and brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (20% EtOAc in hexane, silica) resulted in a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, mixture of rotamers) δ 7.32 (s, 1 H), 6.62 (m, 1 H), 4.37 (m, 1 H), 3.87 (s, 3 H), 3.81 (m, 1 H), 3.28-3.10 (m, 3 H), 2.73 (m, 1 H), 1.31 (m, 3 H), 1.25 (m, 3 H).


25

*8-Bromo-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-bromo-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (21 mg, 0.055 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was

5 diluted with water (5 mL), extracted twice with EtOAc (10 mL), the combined organic phases were washed with brine (10 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated to give 11 mg of a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.29 (s, 1 H), 6.64 (s, 1 H), 3.88 (s, 3 H), 3.02 (m, 2 H), 2.89 (dd,  $J=9$ , 14 Hz, 1 H), 2.80 (m, 1 H), 2.67 (d,  $J=14$  Hz, 1 H), 2.53 (dd,  $J=10$ , 13, 1 H) 1.30 (d,  $J=7$  Hz, 3 H), 1.19 (d,  $J=6$  Hz, 3 H). MS calculated for  $\text{C}_{13}\text{H}_{18}\text{BrNO}+\text{H}^+$ : 284, observed: 284.

**Example 25: 7-Allyloxy-8-bromo-1,4-dimethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




10 *N*-Trifluoroacetyl-8-bromo-1,4-dimethyl-7-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine  
A solution of *N*-trifluoroacetyl-8-bromo-1,4-dimethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.383 g, 1.01 mmol) in dichloromethane (30 mL) was treated with  $\text{BBr}_3$  (2.35 mL of a 1.0M solution in  $\text{CH}_2\text{Cl}_2$ , 2.35 mmol) and stirred overnight while warming to 20°C. The excess  $\text{BBr}_3$  is quenched with water, and the resulting mixture was diluted with ether (100 mL), washed with saturated aqueous  $\text{Na}_2\text{CO}_3$  (50 mL) and brine (50 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.302 g of a white solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , mixture of rotamers)  $\delta$  7.22 (m, 1 H), 6.77 (m, 1 H), 5.34 (s, 1 H), 4.35 (m, 1 H), 3.62 (m, 1 H), 3.24 (m, 1 H), 3.13 (m, 2 H), 2.69 (m, 1 H), 1.31 (m, 3 H), 1.22 (m, 3 H).

20 *N*-Trifluoroacetyl-7-allyloxy-8-bromo-1,4-dimethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine  
A solution *N*-trifluoroacetyl-8-bromo-1,4-dimethyl-7-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.030 g, 0.082 mmol) in dichloromethane (2 mL) was treated with allyl bromide (0.030 g, 0.246 mmol), DBU (0.037 g, 0.246 mmol) and stirred 2 hours at 20°C. The product mixture was diluted with EtOAc (10 mL), washed with 5% aqueous HCl (2 mL), brine (5 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.028 g of a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , mixture of rotamers)  $\delta$  7.32 (s, 1 H), 6.62 (m, 1 H), 6.02 (m, 1 H), 5.45 (d,  $J=17$  Hz, 1 H), 5.30 (d,  $J=1$  Hz, 1 H), 4.58 (s, 2 H), 4.36 (m, 1 H), 3.62 (m, 1 H), 3.23 (m, 1 H), 3.11 (m, 1 H), 2.81 (d,  $J=10$  Hz, 1 H), 2.70 (m, 1 H), 1.34 (m, 3 H), 1.21 (m, 3 H).

*7-Allyloxy-8-bromo-1,4-dimethyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

5 A solution of N-trifluoroacetyl-7-allyloxy-8-bromo-1,4-dimethyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.028 g, 0.069 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3 hours at 20°C. The product mixture was diluted with water (10 mL), extracted twice with EtOAc (10 mL), the combined organic phases were washed with brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.020 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.30 (s, 1 H), 6.64 (s, 1 H), 6.06 (m, 1 H), 5.47 (d, J=17 Hz, 1 H), 5.30 (d, J=11 Hz, 1 H), 4.56 (s, 2 H), 3.03 (m, 2 H), 2.90 (dd, J=9, 14 Hz, 1 H), 2.80 (m, 1 H), 2.65 (d, J=14 Hz, 1 H), 2.55 (dd, J=10, 14 Hz, 1 H), 10 1.77 (bs, 1 H), 1.30 (d, J=7 Hz, 3 H), 1.20 (d, J=6 Hz, 3 H).

**Example 26: (R,S) 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine***N-Trifluoroacetyl-4-chlorophenethylamine*

15 A solution of 4-chlorophenethylamine (1.0 g, 6.4 mmol) in dichloromethane (20 mL) was cooled to 0°C, treated with pyridine (1.0 mL, 12.8 mmol), trifluoracetic anhydride (1.6 g, 7.7 mmol) and then stirred for 1 hour while warming to 20°C. The product mixture was diluted with EtOAc (100 mL), washed sequentially with 10% aqueous HCl (50 mL), water (50 mL), brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 1.6 g of a white solid.

*N-Trifluoroacetyl-2-iodo-4-chlorophenethylamine*

25 A solution of N-trifluoroacetyl-4-chlorophenethylamine (1.6 g, 6.4 mmol) in dichloromethane (20 mL) was treated with bis(pyridine)iodonium(I)tetrafluoroborate (2.6 g, 7.0 mmol), CF<sub>3</sub>SO<sub>3</sub>H (2.1 g, 14.1 mmol) and stirred overnight at 20°C. The product mixture was concentrated, dissolved in EtOAc (100 mL), washed twice with 5% aqueous sodium bisulfite (50 mL), twice with saturated aqueous NaHCO<sub>3</sub>, (50 mL) once with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.94 g of a clear oil. MS calculated for C<sub>10</sub>H<sub>8</sub>ClF<sub>3</sub>INO<sub>2</sub>H: 378, observed: 378.

*N-Allyl, N-trifluoroacetyl-2-iodo-4-chlorophenethylamine*

A solution of N-trifluoroacetyl-2-iodo-4-chlorophenethylamine (0.94 g, 2.4 mmol) in toluene (25 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (0.43 g, 3.12 mmol), KOH (0.40 g, 7.2 mmol), n-Bu<sub>4</sub>NBr (0.077 g, 0.24 mmol) and allyl bromide (0.43 g, 3.6 mmol) sequentially. The 5 mixture was stirred at 80°C for 3.5 hours, cooled to 20°C and acidified with 10% aqueous HCl. The phases were separated, the aqueous phase extracted with ether (100 mL), the combined organic phases were washed with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.76 g of a clear oil. MS calculated for C<sub>13</sub>H<sub>12</sub>ClF<sub>3</sub>INO+H: 418, observed: 418.

10

*N-Trifluoroacetyl-8-chloro-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-allyl, N-trifluoroacetyl-2-iodo-4-chlorophenethylamine (0.76 g, 1.8 mmol) in dimethylformamide (20 mL) was treated with KOAc (0.53 g, 5.4 mmol), n-Bu<sub>4</sub>NBr (0.58 g, 1.8 mmol), PPh<sub>3</sub> (0.047 g, 0.18 mmol), Pd(OAc)<sub>2</sub> (0.041 g, 0.18 mmol) 15 and stirred overnight at 105°C. The product mixture was cooled to 20°C, filtered, diluted with water (100 mL), extracted with ether (3 x 100 mL), the combined organic phases washed with water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10% EtOAc in hexane, silica) resulted in 0.228 g of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (s, 1 H), 7.18 (m, 1 H), 7.04 (m, 1 H), 5.38 (m, 2 H), 5.40 (d, J=16 Hz, 2 H), 3.80 (m, 2 H), 3.00 (m, 2 H). MS calculated for C<sub>13</sub>H<sub>11</sub>ClF<sub>3</sub>NO+H: 290, observed: 290.

20

*N-Trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-chloro-1-methylene-2,3,4,5-tetrahydro-1H-3-benzazepine (0.16 g, 0.55 mmol) in methanol (10 mL) was treated with 10% Pd/C (0.02 g) and stirred 30 minutes under an atmosphere of hydrogen. The product mixture was 25 filtered, concentrated and purified by flash chromatography (5% EtOAc in hexane, silica) resulting in 0.057 g of a white solid. MS calculated for C<sub>13</sub>H<sub>13</sub>ClF<sub>3</sub>NO+H: 292, observed: 292.

30


*8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (65 mg, 0.22 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3.5 hours at 60°C. The product mixture was concentrated,

extracted 3 times with  $\text{CH}_2\text{Cl}_2$  (5 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated to give 35 mg of a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.11 (s, 1 H), 7.05 (d,  $J=8$  Hz, 1 H), 6.98 (d,  $J=8$  Hz, 1 H), 3.1-2.9 (m, 6 H), 2.71 (m, 1 H), 2.68 (bs, 1 H), 1.32 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{11}\text{H}_{14}\text{ClN}+\text{H}^-$ : 196, observed: 196.

5 An additional synthesis has been reported for the preparation of the title compound and the HCl salt in PCT publication WO2005/019179.

**Example 27: (R,S) 7-(2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



10 *N*-Trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

A solution of *N*-trifluoroacetyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.506 g, 1.76 mmol) in dichloromethane (20 mL) was treated with  $\text{BBr}_3$  (4.1 mL of a 1.0M solution in  $\text{CH}_2\text{Cl}_2$ , 4.1 mmol) and stirred overnight while warming to 20°C.

15 The excess  $\text{BBr}_3$  was quenched with water, and the resulting mixture was diluted with ether (200 mL), washed with  $\text{Na}_2\text{CO}_3$  (100 mL) and brine (100 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 0.460 g of a white solid foam. MS calculated for  $\text{C}_{13}\text{H}_{14}\text{F}_3\text{NO}_2+\text{H}^-$ : 274, observed: 274.

20 *N*-Trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine,  
*O*-trifluoromethanesulfonate

A solution of *N*-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (460 mg, 1.76 mmol) in dichloromethane (15 mL) was treated with pyridine (417 mg, 5.27 mmol), trifluoromethanesulfonic anhydride (991 mg, 3.52 mmol) and stirred 1.5 hours at 20°C. The product mixture was diluted with dichloromethane (100 mL), washed with water (50 mL), 5% aqueous HCl (50 mL), saturated aqueous  $\text{NaHCO}_3$  (50 mL), brine (50 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (15% EtOAc in hexane, silica) resulted in 658 mg of a clear oil. MS calculated for  $\text{C}_{14}\text{H}_{13}\text{F}_6\text{NO}_4\text{S}^+\text{H}^-$ : 406, observed: 406.


*N*-Trifluoroacetyl-7-(2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

To a solution of *N*-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate (100 mg, 0.25 mmol) in dimethylformamide (2 mL) was treated with (2-methyl-2*H*-pyrazol-3-yl)-tri-*n*-butyltin (138 mg, 0.37 mmol), LiCl (21 mg, 0.50 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (35 mg, 0.05 mmol) and stirred at 100°C for 4 hours. The product mixture was diluted with EtOAc (20 mL), washed twice with water (10 mL), once with brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (30% EtOAc in hexane, silica) resulted in 80 mg of a clear oil. MS calculated for C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O+H: 338, observed: 338.

*7-(2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

A solution of *N*-trifluoroacetyl-7-(2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (48 mg, 0.14 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and the solution stirred overnight at 20°C. The product mixture was concentrated, extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and the solvent evaporated. Flash chromatography (0-15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, silica) resulted in 30 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48 (s, 1 H), 7.21 (m, 2 H), 7.13 (s, 1 H), 6.27 (s, 1 H), 3.89 (s, 3 H), 3.3-2.9 (m, 9 H), 2.79 (dd, J=7, 14 Hz, 1 H), 1.40 (d, J=8 Hz, 3 H). MS calculated for C<sub>15</sub>H<sub>19</sub>N<sub>3</sub>+H: 242, observed: 242.

**Example 28: (R,S) 7-(4-Bromo-2-methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-Trifluoroacetyl-7-(4-bromo-2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine


To a solution of *N*-trifluoroacetyl-7-(2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (30 mg, 0.082 mmol) in dichloromethane (1 mL) was treated with N-bromosuccinimide (15.3 mg, 0.086 mmol) and stirred overnight at 20°C. The product mixture was absorbed on silica and purified by flash chromatography (2-5%

MeOH in  $\text{CH}_2\text{Cl}_2$ , silica) resulting in 37 mg of a white crystalline solid. MS calculated for  $\text{C}_{17}\text{H}_{17}\text{BrF}_3\text{N}_3\text{O}+\text{H}$ : 416, observed: 416.

5 **7-(4-Bromo-2-methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**

A solution of N-trifluoroacetyl-7-(4-bromo-2-Methyl-2*H*-pyrazol-3-yl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (37 mg, 0.089 mmol) in methanol (2 mL) was treated with of 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was concentrated, extracted 3 times with  $\text{CH}_2\text{Cl}_2$  (5 mL), dried with  $\text{Na}_2\text{SO}_4$  and the solvent evaporated. Flash chromatography (0-15% MeOH in  $\text{CH}_2\text{Cl}_2$ , silica) resulted in 28 mg of a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.50 (s, 1 H), 7.25 (d,  $J=8$  Hz, 1 H), 7.17 (d,  $J=8$  Hz, 1 H), 7.10 (s, 1 H), 3.83 (s, 3 H), 3.17 (m, 1 H), 3.1-2.9 (m, 8 H), 2.80 (dd,  $J=7$ , 13 Hz, 1 H), 2.48 (bs, 1 H), 1.40 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{15}\text{H}_{18}\text{BrN}_3+\text{H}$ : 320, observed: 320.


10 **Example 29: (R,S) 7-(3-Chlorophenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



A solution of N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate (50 mg, 0.123 mmol) in 1,4-dioxane (1.5 mL) was treated with 2-chlorophenylboronic acid (39 mg, 0.243 mmol), CsF (56 mg, 0.37 mmol), water (50 mg, 2.78 mmol),  $\text{Pd}(\text{PPh}_3)_4$  (29 mg, 0.025 mmol) and stirred overnight at 75°C. The product mixture was diluted with  $\text{EtOAc}$  (20 mL), washed with water (10 mL), brine (10 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (10-20%  $\text{EtOAc}$  in hexane, silica) resulted in 45 mg of a clear oil. MS calculated for  $\text{C}_{19}\text{H}_{17}\text{ClF}_3\text{NO}+\text{H}$ : 368, observed: 368. The product (27 mg, 0.073 mmol) was dissolved in methanol (2 mL) treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was concentrated, extracted 3 times with  $\text{CH}_2\text{Cl}_2$  (5 mL), dried with  $\text{Na}_2\text{SO}_4$  and the solvent evaporated to give 18 mg of a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.54 (s, 1 H), 7.42 (d,  $J=6$  Hz, 1 H), 7.35-7.21 (m, 5 H), 3.14 (m, 1 H), 3.1-2.9 (m, 8 H), 2.80 (bm, 2 H), 1.38 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{17}\text{H}_{18}\text{ClN}_3+\text{H}$ : 272,

observed: 272.


**Example 30: (R,S) 7-(2-Chlorophenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



A solution of *N*-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate (50 mg, 0.123 mmol) in 1,4-dioxane (1.5 mL) was treated with 2-chlorophenylboronic acid (39 mg, 0.243 mmol), CsF (56 mg, 0.37 mmol), water (50 mg, 2.78 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (29 mg, 0.025 mmol) and stirred overnight at 75°C. The product mixture was diluted with EtOAc (20 mL), washed with water (10 mL), brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10-20% EtOAc in hexane, silica) resulted in 36 mg of a clear oil. MS calculated for C<sub>19</sub>H<sub>17</sub>ClF<sub>3</sub>NO+H: 368, observed: 368. The product (27 mg, 0.073 mmol) was dissolved in methanol (2 mL) treated with 15% aqueous NaOH (2 mL), and stirred overnight at 10°C. The product mixture was concentrated, extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and the solvent evaporated to give 24 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44 (d, J=8 Hz, 1 H), 7.35-7.22 (m, 5 H), 7.15 (s, 1 H), 3.14 (m, 1 H), 3.1-2.9 (m, 8 H), 2.80 (dd, J=13, Hz, 1 H), 2.51 (bs, 1 H), 1.38 (d, J=8 Hz, 3 H). MS calculated for C<sub>17</sub>H<sub>18</sub>ClN<sub>3</sub>+H: 272, observed: 272.

15

**Example 31: (R,S) 8-Chloro-1-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-Trifluoroacetyl-8-chloro-1-oxo-,3,4,5-trihydro-1*H*-3-benzazepine

A solution of *N*-trifluoroacetyl-8-chloro-1-methylene-3,4,5-trihydro-1*H*-3-benzazepine (0.23 g, 0.80 mmol) in 1:1 methanol/dichloromethane (45 mL) was cooled to -78°C, treated with ozone until the solution turned blue (about 20 minutes), PPh<sub>3</sub> (0.21 g, 0.80 mmol) was added and the resulting solution was stirred 90 minutes while warming to 20°C. The product mixture was concentrated and purified by flash chromatography (30% EtOAc in hexane, silica) resulting in 0.215 g of a white solid. MS calculated for


C<sub>12</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub>+H: 292, observed: 292.

*8-Chloro-1-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine*

5 A solution of N-trifluoroacetyl-8-chloro-1-oxo-3,4,5-trihydro-1H-3-benzazepine (50 mg, 0.17 mmol) in methanol (2 mL) was treated with NaBH<sub>4</sub> and the resulting mixture was stirred 16 hours at 20°C. The white solid product was collected by filtration, washed with water and dried, resulting in 30 mg of a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.39 (s, 1 H), 7.12 (d, J=8 Hz, 1 H), 7.06 (d, J=8 Hz, 1 H), 4.74 (d, J=8 Hz, 1 H), 3.1-2.7 (m, 6 H). MS calculated for C<sub>10</sub>H<sub>12</sub>ClNO+H: 198, observed: 198.

10


**Example 32: (R,S) 8-Bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**



By the same general procedure as in example 26, (R,S) 8-bromo-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was obtained from 4-bromophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.27 (s, 1 H), 7.22 (d, J=8 Hz, 1 H), 6.94 (d, J=8 Hz, 1 H), 3.1-2.85 (m, 6 H), 2.72 (m, 1 H), 2.25 (bs, 1 H), 1.33 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>BrN+H: 240, observed: 240.

15

**Example 33: (R,S) 8-Fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**




20

By the same general procedure as in example 26, (R,S) 8-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine was obtained from 4-fluorophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.00 (dd, J=8, 10 Hz, 1 H), 6.86 (d, J=10 Hz, 1 H), 6.76 (d, J=8 Hz, 1 H), 3.08-2.56 (m, 7 H), 1.85 (bs, 1 H), 1.31 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>FN+H: 180, observed: 180.


25

**Example 34: (R,S) 7-Fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**




By the same general procedure as in example 26, (R,S) 7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from 3-fluorophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09 (dd, J=6, 8 Hz, 1 H), 6.85-6.78 (m, 2 H), 3.10-2.89 (m, 6 H), 2.71 (dd, J=7, 13 Hz, 1 H), 1.91 (bs, 1 H), 1.33 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>14</sub>FN+H: 180, observed: 180.

5 **Example 35: (R,S) 7-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




By the same general procedure as in example 26, (R,S) 7-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from 3-chlorophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.10 (d, J=8 Hz, 1 H), 7.06 (m, 2 H), 3.1-2.9 (m, 6 H), 2.70 (dd, J=13, 7 Hz, 1 H), 1.89 (bs, 1 H), 1.31 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>14</sub>ClN+H: 196, observed: 196.

10 **Example 36: (R,S) 7,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




By the same general procedure as in example 26, (R,S) 7,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from 3,4-dichlorophenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.20 (s, 1 H), 7.16 (s, 1 H), 3.05-2.86 (m, 6 H), 2.71 (dd, J=7, 13 Hz, 1 H), 1.83 (bs, 1 H), 1.33 (d, J=7 Hz, 3 H). MS calculated for C<sub>11</sub>H<sub>13</sub>Cl<sub>2</sub>N+H: 230, observed: 230.

20 **Example 37: (R,S) N-Methyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




25 By the same general procedure as in example 9, (R,S) N-methyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from (R,S) 8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine as a colorless oil. MS calculated for C<sub>12</sub>H<sub>16</sub>ClN+H: 210, observed: 210.

**Example 38: (R,S) 1-Methyl-7-trifluoromethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**


By the same general procedure as in example 26, (R,S) 1-methyl-7-trifluoromethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from 3-trifluoromethoxyphenethylamine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.39 (d, J=8 Hz, 1 H), 7.19 (m, 1 H), 3.46 (m, 2 H), 3.38 (d, J=13 Hz, 1 H), 3.29 (m, 1 H), 3.16 (m, 2 H), 3.05 (dd, J=13, 9 Hz, 1 H), 1.50 (d, J=8 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>14</sub>F<sub>3</sub>NO+H: 246, observed: 246.

10 **Example 39: (R,S) 8-Iodo-1-methyl-7-trifluoromethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




15 By the same general procedure as in example 3, (R,S) 8-iodo-1-methyl-7-trifluoromethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-1-methyl-7-trifluoromethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine as a colorless oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.79 (s, 1 H), 7.25 (s, 1 H), 3.46-3.40 (m, 3 H), 3.28-3.12 (m, 3 H), 3.07 (dd, J=13, 9 Hz, 1 H), 1.47 (d, J=7 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>14</sub>F<sub>3</sub>INO+H: 372, observed: 372.


20 **Example 40: (R,S) N-Propyl-8-iodo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




25 By the same general procedure as in example 10, (R,S) N-Propyl-8-iodo-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from (R,S) 8-iodo-7-methoxy-1-methyl-1,2,4,5-tetrahydro-3*H*-3-benzazepine as a colorless oil. MS calculated for C<sub>15</sub>H<sub>22</sub>INO+H: 360, observed: 360.

**Example 41: (R,S) 1-Ethyl-8-iodo-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**

By the same general procedure as in example 19, (R,S) 1-ethyl-8-iodo-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluorolacetyl-1-ethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine as a colorless oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.47 (s, 1 H), 6.54 (s, 1 H), 3.86 (s, 3 H), 3.20-2.97 (m, 4 H), 2.93-2.75 (m, 3 H), 2.64 (m, 1 H), 1.78 (m, 2 H), 0.95 (dd,  $J$ =8, 8 Hz, 3 H). MS calculated for  $\text{C}_{13}\text{H}_{18}\text{INO}+\text{H}$ : 332, observed: 332.

10 **Example 42: (R,S) 7-(3-Methoxyphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**

By the same general procedure as in example 29, (R,S) 7-(3-Methoxyphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate as a colorless oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.37 (dd,  $J$ =7, 7 Hz, 1 H), 7.30 (m, 2 H), 7.21 (d,  $J$ =7 Hz, 1 H), 7.14 (d,  $J$ =7 Hz, 1 H), 7.09 (s, 1 H), 6.86 (d,  $J$ =8 Hz, 1 H), 3.85 (s, 3 H), 3.2-2.9 (m, 6 H), 2.80 (m, 1 H), 2.64 (bs, 1 H), 1.38 (d,  $J$ =7 Hz, 3 H). MS calculated for  $\text{C}_{18}\text{H}_{21}\text{NO}+\text{H}$ : 268, observed: 268.


20 **Example 43: (R,S) 7-(2,6-difluorophenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**

By the same general procedure as in example 29, (R,S) 7-(2,6-difluorophenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate as a

25


colorless oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35-7.10 (m, 5 H), 6.95 (dd,  $J=7, 8$  Hz, 1 H), 3.2-2.9 (m, 6 H), 2.79 (dd,  $J=8, 13$  Hz, 1 H), 2.70 (bs, 1 H), 1.38 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{17}\text{H}_{17}\text{F}_2\text{N}+\text{H}$ : 274, observed: 274.

5 **Example 44:** (R,S) 7-(2-fluorophenyl)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine




By the same general procedure as in example 29, (R,S) 7-(2-fluorophenyl)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-8-chloro-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine as a colorless oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35-7.23 (m, 3 H), 7.19-7.09 (m, 2 H), 7.03 (s, 1 H), 3.15-2.85 (m, 7 H), 2.76 (dd,  $J=8, 13$  Hz, 1 H), 1.36 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{17}\text{H}_{17}\text{ClF}_2\text{N}+\text{H}$ : 290, observed: 290.

15 **Example 45:** (R,S) 7-(2-Trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine




By the same general procedure as in example 29, (R,S) 7-(2-trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate as a colorless oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.71 (d,  $J=8$  Hz, 1 H), 7.52 (dd,  $J=7, 8$  Hz, 1 H), 7.42 (dd,  $J=7, 8$  Hz, 1 H), 7.31 (d,  $J=7$  Hz, 1 H), 7.17 (d,  $J=8$  Hz, 1 H), 7.11 (d,  $J=8$  Hz, 1 H), 3.15 (m, 1 H), 3.1-2.9 (m, 5 H), 2.76 (dd,  $J=8, 13$  Hz, 1 H), 2.37 (bs, 1 H), 1.38 (d,  $J=8$  Hz, 3 H). MS calculated for  $\text{C}_{18}\text{H}_{18}\text{F}_3\text{N}+\text{H}$ : 306, observed: 306.

**Example 46: (R,S) 7-(3-Trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




By the same general procedure as in example 29, (R,S) 7-(3-trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (s, 1 H), 7.73 (d, J=8 Hz, 1 H), 7.57-7.48 (m, 2 H), 7.38 (d, J=8 Hz, 1 H), 7.30 (s, 1 H), 7.24 (d, J=7 Hz, 1 H), 3.16 (m, 1 H), 3.1-2.9 (m, 6 H), 2.79 (dd, J=8, 13 Hz, 1 H), 1.38 (d, J=8 Hz, 3 H). MS calculated for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N+H: 306, observed: 306.

**Example 47: (R,S) 7-(4-Trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



By the same general procedure as in example 29, (R,S) 7-(4-trifluoromethylphenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from N-trifluoroacetyl-7-hydroxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, *O*-trifluoromethanesulfonate as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 4 H), 7.38 (d, J=8 Hz, 1 H), 7.31 (s, 1 H), 7.24 (d, J=8 Hz, 1 H), 3.15 (m, 1 H), 3.1-2.9 (m, 5 H), 2.80 (dd, J=8, 13 Hz, 1 H), 2.48 (bs, 1 H), 1.38 (d, J=8 Hz, 3 H). MS calculated for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N+H: 306, observed: 306.


**Example 48: (R,S) 8-(2-Chlorophenyl)-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



25 A solution of N-trifluoroacetyl-8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-


benzazepine (84 mg, 0.229 mmol) in dimethylformamide (2.5 mL) was treated with 2-chlorophenylboronic acid (43 mg, 0.275 mmol), CsF (52 mg, 0.34 mmol), water (70 mg, 3.9 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (27 mg, 0.023 mmol) and stirred overnight at 75°C. The product mixture was diluted with EtOAc (20 mL), washed with water (10 mL), brine (10 mL), 5 dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (10-20% EtOAc in hexane, silica) resulted in 36 mg of a clear oil. MS calculated for C<sub>19</sub>H<sub>17</sub>ClF<sub>3</sub>NO<sub>2</sub>H: 368, observed: 368. The product (39 mg, 0.106 mmol) was dissolved in methanol (2 mL) treated with 15% aqueous NaOH (2 mL), and stirred overnight at 20°C. The product mixture was concentrated, extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and 10 the solvent evaporated to give 18 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.44 (d, J=8 Hz, 1 H), 7.35-7.17 (m, 5 H), 7.12 (d, J=8 Hz, 1 H), 3.14 (m, 1 H), 3.1-2.9 (m, 5 H), 2.79 (dd, J=7, 13 Hz, 1 H), 2.36 (bs, 1 H), 1.36 (d, J=7 Hz, 3 H). MS calculated for 15 C<sub>17</sub>H<sub>18</sub>ClN<sub>3</sub>H: 272, observed: 272.

Example 49: (R,S) 7-Methoxy-1-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-3-benzazepine



A solution of N-trifluoromethylacetyl-8-iodo-7-methoxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine (135 mg, 0.327 mmol) in dimethylformamide (3 mL) and 20 toluene (0.5 mL) was treated with sodium trifluoroacetate (133 mg, 0.981 mmol), copper (I) iodide (124 mg, 0.654 mmol) and the toluene distilled off to remove any residual water. The reaction mixture was stirred at 155°C for 3.5 hours, diluted with EtOAc, filtered, absorbed on silica and purified by flash chromatography (10% EtOAc in hexane, silica) resulting in 26 mg of a colorless oil. MS calculated for C<sub>15</sub>H<sub>15</sub>F<sub>3</sub>NO<sub>2</sub>H: 356, observed: 356. The intermediate (26 mg, 0.073 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred 0.5 hours at 50°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 14 mg of a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32 (s, 1 H), 6.73 (s, 1 H), 3.89 (s, 3 H), 3.1-2.9 (bm, 6 H), 2.75 (bm, 1 H), 2.23 (bs, 1 H), 1.36 (d, J=8 Hz, 3 H). MS calculated for 25 C<sub>13</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>2</sub>H: 260, observed: 260.

**Example 50: (R,S) 7-Methoxy-1-methyl-8-pentafluoroethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**




5 A solution of N-trifluoromethylacetyl-8-iodo-7-methoxy-1-methyl-1,2,4,5-tetrahydro-3*H*-3-benzazepine (100 mg, 0.242 mmol) in dimethylformamide (3 mL) and toluene (1 mL) was treated with sodium pentafluoropropionate (64 mg, 0.344 mmol), copper (I) iodide (92 mg, 0.484 mmol) and the toluene distilled off to remove any residual water. The reaction mixture was stirred at 160°C for 3.5 hours, diluted with EtOAc, filtered, absorbed on silica and purified by flash chromatography (10% EtOAc in hexane, silica) resulting in 22 mg of a colorless oil. MS calculated for  $C_{16}H_{15}F_8NO_2+H$ : 406, observed: 406. The intermediate (22 mg, 0.054 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred 0.5 hours at 50°C. The product mixture was diluted with water (5 mL), extracted twice with EtOAc (5 mL), the combined organic phases were washed with brine (5 mL), dried with  $Na_2SO_4$  and concentrated to give 14 mg of a colorless oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.25 (s, 1 H), 6.74 (s, 1 H), 3.85 (s, 3 H), 3.1-2.9 (bm, 6 H), 2.76 (bm, 1 H), 2.37 (bs, 1 H), 1.35 (d,  $J=8$  Hz, 3 H). MS calculated for  $C_{14}H_{16}F_8NO+H$ : 310, observed: 310.

10

15


**Example 51: (R,S) 8-Trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



20 By the same general procedure as in example 26, (R,S) 8-trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine was obtained from 4-trifluoromethylphenethylamine as a colorless oil.  $^1H$  NMR (400 MHz, DMSO)  $\delta$  7.55 (d,  $J=8$  Hz, 1 H), 7.49 (s, 1 H), 7.43 (d,  $J=8$  Hz, 1 H), 3.55-3.50 (m, 1 H) 3.43-3.23 (m, 7 H), 3.13 (dd,  $J=16$ , 7 Hz, 1 H), 3.0-2.91 (m, 2 H), 1.36 (d,  $J=7$  Hz, 3 H). MS calculated for  $C_{12}H_{14}F_3N+H$ : 230.19, observed: 230.4


25

**Example 52: (R,S) 8-bromo-1-methoxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



A solution of 8-bromo-1-hydroxymethyl-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine (0.075 g, 0.26 mmol) in dichloromethane (2 mL) was treated with  $\text{BOC}_2\text{O}$  (0.062 g, 0.29 mmol), and stirred overnight at 20°C. The product was absorbed on silica and purified by flash chromatography (33%  $\text{EtOAc}$  in hexane, silica) resulting in 0.034 g of a clear oil. MS calculated for  $\text{C}_{17}\text{H}_{24}\text{BrNO}_4+\text{H}$ : 386, observed: 386. The  $\text{BOC}$ -protected intermediate was dissolved in dimethylformamide (1 mL), treated with excess 5 NAH and excess iodomethane sequentially, and then stirred for 1 hour at 20°C. The reaction mixture was quenched with water (5 mL), extracted twice with  $\text{EtOAc}$  (5 mL), the combined organic phases were washed with brine (5 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated to give 0.019 g of a clear oil. MS calculated for  $\text{C}_{18}\text{H}_{26}\text{BrNO}_4+\text{H}$ : 400, observed: 400. The N- $\text{BOC}$  protected methylether was then treated with 4M HCl in 10 dioxane (1 mL) and stirred 2 hours at 20°C. Evaporation resulted in 0.009 g of the desired product as a clear oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.30 (s, 1 H), 6.92 (s, 1 H), 3.87 (s, 3 H), 3.65 (s, 3 H) 3.5-3.1 (m, 9 H). MS calculated for  $\text{C}_{15}\text{H}_{18}\text{BrNO}_2+\text{H}$ : 300, observed: 300.

15 **Example 53: (R,S) 8-Chloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine**



*N*-Crotol, *N*-trifluoroacetyl-2-iodo-4-chlorophenethylamine

20 A solution of *N*-trifluoroacetyl-2-iodo-4-chlorophenethylamine (6.2 g, 15.8 mmol) in dimethylformamide (350 mL) was treated with  $\text{K}_2\text{CO}_3$  (15.8 g, 114 mmol) and crotol bromide (6.0 g, 44 mmol) sequentially, the mixture was stirred at 60°C for 16 hours and then cooled to 20°C. The mixture was diluted with  $\text{EtOAc}$  (350 mL), washed with water (3 x 300 mL), dried with  $\text{Na}_2\text{SO}_4$  and concentrated. Flash chromatography (5-15%  $\text{EtOAc}$  in hexane) resulted in 2.5 g of a clear oil. MS calculated for  $\text{C}_{14}\text{H}_{14}\text{ClF}_3\text{INO}+\text{H}$ : 432, observed: 432.

*N-Trifluoroacetyl-8-chloro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine*


A solution of N-crotyl, N-trifluoroacetyl-1-iodo-4-chlorophenethylamine (2.5 g, 5.8 mmol) in dimethylformamide (250 mL) was treated with KOAc (1.07 g, 10.9 mmol), 5 n-Bn<sub>2</sub>Et<sub>2</sub>NBr (1.33 g, 5.84 mmol), Pd(OAc)<sub>2</sub> (0.063 g, 0.28 mmol) and stirred overnight at 77°C. The product mixture was cooled to 20°C, filtered, diluted with water (100 mL), extracted with EtOAc (3 x 100 mL), the combined organic phases washed with water (100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. Flash chromatography (2-20% EtOAc in hexane, silica) resulted in 0.339 g of a clear oil. The product, which was 10 assumed to be a mixture of double-bond isomers, was dissolved in methanol (50 mL) treated with Et<sub>3</sub>N (0.2 mL), 10% Pd/C (0.10 g) and stirred 16 hours under 100 psi of hydrogen. The product mixture was filtered, concentrated and purified by flash chromatography (5% EtOAc in hexane, silica) resulting in 0.20 g of a white solid. MS calculated for C<sub>14</sub>H<sub>15</sub>ClF<sub>3</sub>NO+H: 306, observed: 306.

15

*8-Chloro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-chloro-1-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine (63 mg, 0.207 mmol) in methanol (2 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3.5 hours at 60°C. The product mixture was concentrated, 20 extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 35 mg of a clear oil. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.2 (m, 3 H), 3.3-3.0 (m, 7 H), 1.9-1.6 (m, 2 H), 0.91 (t, J=7 Hz, 3 H). MS calculated for C<sub>12</sub>H<sub>16</sub>ClN+H: 210, observed: 210.

25

**Example 54: (R,S) 8-Chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine**

25

*N-Trifluoroacetyl-8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine*

A solution of N-trifluoroacetyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2.5 g, 8.5 mmol) in 1,2-dichloroethane (15 mL) was treated with Selectfluor (3.9 g, 11 mmol), trifluoromethanesulfonic acid (8 mL, 90 mmol) and stirred 60 hours at 75°C. The product mixture was poured into water (200 mL), extracted with EtOAc (200 mL), the organic phase washed with saturated aqueous NaHCO<sub>3</sub> (2 x 100 mL), brine (100 mL), dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by flash 30 chromatography.

chromatography (6 % EtOAc in hexane, silica) resulting in 1.6 g of a white solid. MS calculated for  $C_{13}H_{12}ClF_4NO+H$ : 310, observed: 310.

*8-Chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine*

5 A solution of N-trifluoroacetyl-8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (160 mg, 0.22 mmol) in methanol (3 mL) was treated with 15% aqueous NaOH (2 mL), and stirred for 3.5 hours at 25°C. The product mixture was concentrated, extracted 3 times with  $CH_2Cl_2$  (5 mL), dried with  $Na_2SO_4$  and concentrated to give 93 mg of a clear oil.  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.11 (m, 1 H), 6.85 (m, 1 H), 3.05-2.95 (m, 3 H), 2.95-2.80 (m, 3 H), 2.68 (m, 1 H), 2.38 (bm, 1 H), 1.31 (m, 3 H). MS calculated for  $C_{11}H_{13}ClFN+H$ : 214, observed: 214.

10

**Example 55 Separation of enantiomers for selected compounds of the invention**

15 The following compounds were separated into their respective enantiomers using a Varian ProStar HPLC system with a 20 mm x 250 mm Chiralcel OD chiral column, eluting with 0.2 % diethylamine in various concentrations of isopropanol (IPA) in hexanes, see Table 2 below. In some cases, the separations were performed on the intermediate trifluoroacetamide protected amines.

Table 2

Example	Enantiomer	Retention time for the free amine (mins)	Retention time for the trifluoroacetamide	Conditions
1	1	21.9		5% IPA in hexane
	2	24.5		10 mL/min
2	1	42		5% IPA in hexane
	2	47		9 mL/min
3	1	20.8		5% IPA in hexane
	2	24.2		10 mL/min
19	1	34.9		1% IPA in hexane
	2	39.5		9 mL/min
26	1		23.8 <sup>1</sup>	5% IPA in hexane
	2		29.2 <sup>2</sup>	7 mL/min
37	1		23.8 <sup>3</sup>	5% IPA in hexane

Example	Enantiomer	Retention time for the free amine (mins)	Retention time for the trifluoroacetamide	Conditions
	2		29.2 <sup>4</sup>	7 mL/min
51	1		18.6 <sup>5</sup>	1% IPA in hexane
	2		21.4 <sup>6</sup>	9 mL/min
53	1		13.7 <sup>7</sup>	5% IPA in hexane
	2		20.2 <sup>8</sup>	10 mL/min

<sup>1</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 1 of Compound 26.

<sup>2</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 2 of Compound 26.

<sup>3</sup> The separated trifluoroacetamide enantiomer was hydrolyzed and subsequently N-methylated to give Enantiomer 1 of Compound 37.

<sup>4</sup> The separated trifluoroacetamide enantiomer was hydrolyzed and subsequently N-methylated to give Enantiomer 2 of Compound 37.

<sup>5</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 1 of Compound 51.

<sup>6</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 2 of Compound 51.

<sup>7</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 1 of Compound 53.

<sup>8</sup> The separated trifluoroacetamide enantiomer was hydrolyzed to give Enantiomer 2 of Compound 53.

### Example 56

#### Intracellular IP<sub>3</sub> Accumulation Assay

20 HEK293 cells were transfected in 15cm sterile dishes with or without (control)

16 $\mu$ g of human 5-HT<sub>2C</sub> receptor cDNA using 25 $\mu$ l of lipofectamine. Cells were then incubated for 3-4 hours at 37°C/5%CO<sub>2</sub> and then transfection media was removed and replaced with 100 $\mu$ l of DMEM. Cells were then plated onto 100cm sterile dishes. The next day cells were plated into 96 well PDL microtiter plates at a density of 55K/0.2ml.

25 Six hours latter, media was exchanged with [<sup>3</sup>H]inositol (0.25  $\mu$ Ci/well) in inositol free DMEM and plates were incubated at 37°C/5%CO<sub>2</sub> overnight. The next day, wells were aspirated and 200 $\mu$ l of DMEM containing test compound, 10 $\mu$ M pargyline, and 10mM LiCl was added to appropriate wells. Plates were then incubated at 37°C/5%CO<sub>2</sub> for three hours followed aspiration and by addition of fresh ice cold stop solution (1M KOH, 19mM

30 Na-borate, 3.8 mM EDTA) to each well. Plates were kept on ice for 5-10 min and the wells were neutralized by addition of 200 $\mu$ l of fresh ice cold neutralization solution (7.5% HCl). Plates were then frozen until further processing is desired. The lysate was then

transferred into 1.5 ml Eppendorf tubes and 1 ml of chloroform/methanol (1:2) was added/tube. The solution was vortexed for 15 seconds and the upper phase was applied to a Biorad AG1-X8™ anion exchange resin (100-200 mesh). First, the resin was washed with water at 1:1.25 W/V and 0.9 ml of upper phase was loaded onto the column. The column was then washed with 10 ml of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates were eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/ 1 M ammonium formate. The columns were regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with dd H<sub>2</sub>O and stored at 4°C in water.

10 The biological activities in the IP Accumulation Assay for several representative compounds are shown in Table 3 below:

Table 3

Compound (Example Number)	5-HT <sub>2C</sub> (EC <sub>50</sub> ) <sup>*</sup> IP Accumulation Assay (nM)
1	4.2
2	4.5
3	1.4
4	2.1
5	12.1
12	6.3
19	18
26	5.8
32	2.1

\* Reported values are averages of at least two trials.

15 The majority of the other compounds of the Examples were tested at least once, and they showed activities in the IP Accumulation Assay in the range between ~1.4 nM and ~5 μM.

#### Example 57

##### 20 Inhibition of food intake in food-deprived rats

Male Sprague-Dawley rats (250-350g) were deprived of food overnight prior to testing. Prior to food deprivation, the animals were weighed and separated into treatment groups in order to balance groups according to body weight. On the test day, animals were

placed into individual cages (no bedding) at 9:00am with free access to water. At 10:00am, animals were injected with test compound (p.o., i.p., or s.c.) and then presented with a pre-weighed amount of food in a dish either 60min (p.o.) or 30min (i.p. and s.c.) after drug administration. Food consumption over different time points was then 5 determined by weighing the food cup at 1, 2, 4, and 6hr after the food was presented. Thus, food consumption was measured at 2, 3, 5, and 7hr post-injection in p.o. studies, and at 1.5, 2.5, 4.5, and 6.5hr post-injection in i.p. and s.c. studies.

Figures 1A-G illustrate the effects of seven different compounds on food intake in 10 food-deprived rats. All compounds inhibited food intake dose-dependently. This effect was consistently most pronounced over the first 1hr after food presentation. Some compounds (Figures 1A, 1C, and 1E) maintained an inhibitory effect on food intake relative to vehicle-treated controls at 6hr after food presentation. Compounds were also shown to be effective via all routes of administration including p.o.

15 **Example 58**

**Inhibition of food intake in food-deprived rats using a selective 5HT-2C receptor agonist alone, phentermine alone, or a combination of the two compounds.**

Male SD rats, weight 250-275g, were purchased from Harlan and housed 4 per 20 cage in an animal facility in reverse day-light. Water and Chow was available (LabDiet 8604) *ad libitum* for two weeks. The animals were handled for 2 occasions during this time. On the morning of the study, the animals were single-housed with no food or bedding and dosed perorally with 1 ml/kg of compound or vehicle 30 minutes prior to lights out. At lights out, the animals were given a pre-weighed amount of chow and placed near the food bowl. Two hours later the remaining chow was weighed and the study 25 concluded.

Figure 2 shows the effect on feeding of the selective 5HT-2C receptor agonist 8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Cmpd A), phentermine, and the combination. A synthesis example for 8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Cmpd A) can be found in Example 2 herein.

30

**Example 59**

**Inhibition of food intake in food-deprived rats using a selective 5HT-2C receptor agonist alone, phentermine alone, or a combination of the two compounds.**

Female (weight 225-250g) and male (weight 250-275g) Sprague-Dawley (SD) rats

were purchased from Harlan (San Diego, CA) and housed 4 per cage in a temperature controlled environment under a 17h/7h light/dark cycle (lights out at 10:00am). Water and Chow was available (LabDiet 8604) *ad libitum* for two weeks. The animals were handled for 2 occasions during this time. On the morning of the study, the animals were 5 individually housed with no food or bedding and dosed perorally with 1 ml/kg of compound or vehicle 30 minutes prior to lights out. At lights out, the animals were given a pre-weighed amount of chow and placed near the food bowl. Two hours later the remaining chow was weighed and the study concluded.

10 Figure 3 shows the effect of the selective 5HT-2C receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Compound B), phentermine, and the combination on food intake. A synthesis example for (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine (Compound B) can be found in Example 26 herein.

15 The effect of Compound B, phentermine, and the combination on food intake in female rats is shown in Figure 3A. For analysis, the data was subjected to a two-way analysis of variance (ANOVA) with phentermine and Compound B as independent factors. The analysis revealed a significant interaction between the two factors  $[F(1,29)=31.6, p<0.01]$ . Posthoc pairways comparisons using the Bonferroni multiple comparison test revealed the Compound B + phentermine combination to differ significantly from all other groups ( $p<0.01$ , see Figure 3A), evidencing a supra additive (synergistic) effect for the inhibition of food intake. No other significant differences 20 between groups were observed.

25 The effect of Compound B, phentermine, and the combination on food intake in male rats is shown in Figure 3B. For analysis, the data was subjected to a two-way analysis of variance (ANOVA) with phentermine and Compound B as independent factors. The analysis revealed a significant interaction between the two factors  $[F(1,29)=12.7, p<0.01]$ . Posthoc pairways comparisons using the Bonferroni multiple comparison test revealed the Compound B + phentermine combination to differ significantly from all other groups ( $p<0.01$ , see Figure 3B), evidencing a supra additive (synergistic) effect for the inhibition of food intake. No other significant differences 30 between groups were observed.

**Example 60****Inhibition of food intake in food-deprived rats using a selective 5HT-2C receptor agonist alone, phentermine alone, or a combination of the two compounds.**

Male and female Sprague-Dawley (SD) rats (weight 250-275g) were purchased 5 from Harlan (San Diego, CA) and housed 4 per cage in a temperature controlled environment under a 17h/7h light/dark cycle (lights out at 10:00am). Water and Chow was available (LabDiet 8604) *ad libitum* for two weeks. The animals were handled for 2 occasions during this time. On the morning of the study, the animals were individually housed with no food or bedding and dosed perorally with 1 ml/kg of compound or vehicle 10 30 minutes prior to lights out. At lights out, the animals were given a pre-weighed amount of chow and placed near the food bowl. Two hours later the remaining chow was weighed and the study concluded.

Figures 4A and 4B show the supra additive (synergistic) effect of phentermine and 15 the selective 5HT-2C receptor agonist (*R*)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine (Cmpd C) on food intake in female (Figure 4A) and male (Figure 4B) rats.

Compound C is a selective 5HT-2C receptor agonist which lies outside of Formula I as disclosed herein. Compound C was prepared in a similar manner as described in PCT publication WO 2005/016902 (see Example 3.2 therein) using 2-bromo-4-chloro-1-fluorobenzene as the starting material.


20 It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

25 Those skilled in the art will appreciate that numerous changes and modifications can be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

**What is claimed is:**

1. A composition comprising phentermine and a selective 5HT-2C receptor agonist.

5 2. The composition according to claim 1, wherein said selective 5HT-2C receptor agonist has Formula (I):



or a pharmaceutically acceptable salt, solvate or hydrate thereof  
wherein:

10  $R_1$  is H or  $C_{1-8}$  alkyl;  
 $R_2$  is  $C_{1-8}$  alkyl,  $-CH_2-O-C_{1-8}$  alkyl,  $-C(=O)-O-C_{1-8}$  alkyl,  $-C(=O)-NH-C_{1-8}$  alkyl, OH, or  $CH_2OH$ ;  
 $R_{2a}$  is H;  
or  $R_2$  and  $R_{2a}$  together form  $-CH_2-CH_2-$ ;

15  $R_3$  and  $R_4$  are each independently H, halogen, perhaloalkyl, CN, OR<sub>5</sub>, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, OH, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from  $C_{1-8}$  alkyl, halogen, perhaloalkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and  $C_{1-8}$  alkyl;

20 or  $R_3$  and  $R_4$  together with the atoms to which they are attached can form a 5- or 6-member heterocyclic ring having one O atom;  
each  $R_5$  is independently  $C_{1-8}$  alkyl,  $C_{1-8}$  alkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or perhaloalkyl, or allyl; and  
 $R_6$  is H or  $C_{1-8}$  alkyl.

25

3. The composition according to claim 2 wherein:  
 $R_3$  is halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from  $C_{1-8}$  alkyl, halogen, perhaloalkyl, and alkoxy, and said heteroaryl can be

30

optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl; and

5 R<sub>4</sub> is H, halogen, perhaloalkyl, CN, SR<sub>5</sub>, NHR<sub>5</sub>, N(R<sub>5</sub>)<sub>2</sub>, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, perhalo alkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

10 wherein heteroaryl is pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, furanyl, pyranyl, thieryl, benzimidazolyl, quinolinyl, isoquinolinyl, oxazolyl, thiazolyl or thiadiazolyl.

4. The composition according to claim 2 or 3 wherein R<sub>1</sub> is H.
5. The composition according to claim 2 or 3 wherein R<sub>1</sub> is methyl.
- 15 6. The composition according to any one of claims 2 to 5 wherein R<sub>2</sub> is methyl, ethyl, n-propyl or isopropyl.
7. The composition according to any one of claims 2 to 5 wherein R<sub>2</sub> is methyl or ethyl.
- 20 8. The composition according to any one of claims 2 to 5 wherein R<sub>2</sub> and R<sub>2a</sub> together form -CH<sub>2</sub>CH<sub>2</sub>-.
- 25 9. The composition according to any one of claims 2 to 8 wherein R<sub>3</sub> is chlorine.
10. The composition according to any one of claims 2 to 8 wherein R<sub>3</sub> is bromine.
11. The composition according to any one of claims 2 to 8 wherein R<sub>3</sub> is perhaloalkyl.
- 30 12. The composition according to any one of claims 2 to 8 wherein R<sub>3</sub> is CF<sub>3</sub>.
13. The composition according to any one of claims 2 to 8 wherein R<sub>3</sub> is selected from the group consisting of thieryl, furanyl, pyrrolyl, pyrazolyl and imidazolyl.

14. The composition according to any one of claims 2 to 13 wherein R<sub>4</sub> is selected from the group consisting of thiethyl, furanyl, pyrrolyl, pyrazolyl and imidazolyl optionally substituted with one or two substituents selected from halogen or methyl.

5

15. The composition according to any one of claims 2 to 13 wherein R<sub>4</sub> is phenyl optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy.

10

16. The composition according to claim 2 wherein:

R<sub>2</sub> is methyl, ethyl, isopropyl, or CH<sub>2</sub>OH; or R<sub>2</sub> and R<sub>2a</sub> taken together form -CH<sub>2</sub>CH<sub>2</sub>-;

R<sub>3</sub> is halogen, or a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S, and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl;

15

R<sub>4</sub> is H, a 5-membered heteroaryl ring having up to two heteroatoms selected from O, N and S and up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, or phenyl optionally substituted with up to two substituents selected from C<sub>1-8</sub> alkyl, halogen, and alkoxy;

20

R<sub>6</sub> is H or methyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

17. The composition according to claim 2 wherein:

25

R<sub>1</sub> is H;

R<sub>2</sub> is methyl;

R<sub>3</sub> is chlorine, bromine, or thiencyl;

R<sub>4</sub> is pyrazolyl-3-yl or phenyl wherein said pyrazolyl-3-yl optionally has up to two substituents selected from halogen and C<sub>1-8</sub> alkyl, and said phenyl optionally has a single halogen substituent; and

30

R<sub>6</sub> is H; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

18. The composition according to claim 2 wherein:

R<sub>1</sub> is H or Me;

R<sub>2</sub> is Me, Et, or OH;  
R<sub>2a</sub> is H;  
R<sub>3</sub> is F, Cl, Br, I, CF<sub>3</sub>, or 2-chlorophenyl;  
R<sub>4</sub> is H; and  
R<sub>6</sub> is H.

5

19. The composition according to claim 2 wherein:

R<sub>1</sub> is H;  
R<sub>2</sub> is C<sub>1-8</sub> alkyl;  
R<sub>2a</sub> is H;  
R<sub>3</sub> is halogen;  
R<sub>4</sub> is H; and  
R<sub>6</sub> is H.

10

15 20. The composition according to claim 1 or 2 wherein said selective 5HT-2C receptor agonist is selected from the group consisting of:

8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-bromo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-iodo-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-trifluoromethyl-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-trifluoromethyl-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-bromo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-iodo-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
7,8-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
7,8-dichloro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
8-chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and  
8-chloro-7-fluoro-1-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
30 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

20

25

21. The composition according to claim 1 or 2 wherein said selective 5HT-2C receptor agonist is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. The composition according to any one of claims 1 to 21 further comprising a pharmaceutically acceptable carrier.

5 23. A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal.

10 24. A method in accordance with claim 23, wherein the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in decreasing food intake in said mammal.

15 25. A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in inducing satiety in said mammal.

20 26. A method in accordance with claim 25, wherein the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in inducing satiety in said mammal.

25 27. A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in controlling weight gain in said mammal.

30 28. A method in accordance with claim 27, wherein the amount of (R)-8-chloro-1-

methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in controlling weight gain in said mammal.

5        29.      A method of prophylaxis or treatment of obesity comprising administering to a patient in need of such prophylaxis or treatment a therapeutically effective amount of a combination comprising an amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and an amount of phentermine, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine and phentermine are provided in amounts to give a synergistic effect in decreasing food intake in said mammal.

10       30.      A method in accordance with claim 29, wherein the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine alone and the amount of phentermine alone are therapeutically sub-effective in decreasing food intake in said mammal.

15       31.      A composition according to any one of claims 1 to 21 for use in a method of treatment of the human or animal body by therapy.

20       32.      A composition according to any one of claims 1 to 21 for use in a method of treatment of a 5HT2C disorder of the human or animal body by therapy.

25       33.      A composition according to any one of claims 1 to 21 for use in a method of prophylaxis or treatment of obesity of a mammal.

30       34.      A composition according to any one of claims 1 to 21 for use in a method of decreasing food intake of a mammal.

35.      A composition according to any one of claims 1 to 21 for use in a method of inducing satiety in a mammal.

36.      A composition according to any one of claims 1 to 21 for use in a method of controlling weight gain of a mammal.

37. Use of a composition according to any one of claims 1 to 21 for the manufacture of a medicament for use in the prophylaxis or treatment of a 5HT2C disorder of the human or animal body by therapy.
- 5 38. Use of a composition according to any one of claims 1 to 21 for the manufacture of a medicament for use in the prophylaxis or treatment of obesity of a mammal.
39. Use of a composition according to any one of claims 1 to 21 for the manufacture of a medicament for use in a method of decreasing food intake of a mammal.
- 10 40. Use of a composition according to any one of claims 1 to 21 for the manufacture of a medicament for use in a method of inducing satiety in a mammal.
- 15 41. Use of a composition according to any one of claims 1 to 21 for the manufacture of a medicament for use in a method of controlling weight gain of a mammal.

20




Figure 1A

## B. Compound 3




Figure 1B




Figure 1C




Figure 1D




Figure 1E




Figure 1F




Figure 1G




Figure 2

Supra additive effects on  
feeding  
(Females; n=7-10 animals)




Figure 3A

Supra additive effects on  
feeding  
(Males; n=7-10 animals)




Figure 3B




Figure 4A

Supra additive effects on  
feeding  
(Males; n=6-8 animals)




Figure 4B